

10/040,647

=> d his

(FILE 'HOME' ENTERED AT 15:40:36 ON 14 NOV 2006)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 15:41:25 ON 14 NOV 2006

L1 38020 S SERINE (W) PROTEINASE?
L2 8014433 S CLON? OR EXPRESS? OR RECOMBINANT
L3 12818 S L1 AND L2
L4 6935 S HUMAN AND L3
L5 0 S E ANTALIS T M/AU
E ANTALIS T M/AU
L6 204 S E3
E HOOPER J D/AU
L7 89 S E3
L8 268 S L6 OR L7
L9 38 S L4 AND L8
L10 26 DUP REM L9 (12 DUPLICATES REMOVED)
L11 214 S HUMAN (W)L1
L12 12818 S L2 AND L3
L13 129 S L2 AND L11
L14 85 DUP REM L13 (44 DUPLICATES REMOVED)

=>

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal652mxm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 5 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6 SEP 11 CA/CAplus enhanced with more pre-1907 records
NEWS 7 SEP 21 CA/CAplus fields enhanced with simultaneous left and right
truncation
NEWS 8 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new
classification scheme
NEWS 12 OCT 19 LOGOFF HOLD duration extended to 120 minutes
NEWS 13 OCT 19 E-mail format enhanced
NEWS 14 OCT 23 Option to turn off MARPAT highlighting enhancements available
NEWS 15 OCT 23 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 16 OCT 23 The Derwent World Patents Index suite of databases on STN
has been enhanced and reloaded
NEWS 17 OCT 30 CHEMLIST enhanced with new search and display field
NEWS 18 NOV 03 JAPIO enhanced with IPC 8 features and functionality
NEWS 19 NOV 10 CA/CAplus F-Term thesaurus enhanced
NEWS 20 NOV 10 STN Express with Discover! free maintenance release Version
8.01c now available
NEWS 21 NOV 13 CA/CAplus pre-1967 chemical substance index entries enhanced
with preparation role

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:40:36 ON 14 NOV 2006

=> s serine (w) proteinase?

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'MEDLINE' ENTERED AT 15:41:25 ON 14 NOV 2006

FILE 'EMBASE' ENTERED AT 15:41:25 ON 14 NOV 2006

Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 15:41:25 ON 14 NOV 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 15:41:25 ON 14 NOV 2006

COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'SCISEARCH' ENTERED AT 15:41:25 ON 14 NOV 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'HCAPLUS' ENTERED AT 15:41:25 ON 14 NOV 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'NTIS' ENTERED AT 15:41:25 ON 14 NOV 2006

Compiled and distributed by the NTIS, U.S. Department of Commerce.

It contains copyrighted material.

All rights reserved. (2006)

FILE 'LIFESCI' ENTERED AT 15:41:25 ON 14 NOV 2006

COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

=> s serine (w) proteinase?

L1 38020 SERINE (W) PROTEINASE?

=> s clon? or express? or recombinant

L2 8014433 CLON? OR EXPRESS? OR RECOMBINANT

=> s l1 and l2

L3 12818 L1 AND L2

=> s human and l3

L4 6935 HUMAN AND L3

=> s e antalis t m/au

L5 0 E ANTALIS T M/AU

=> e antalis t m/au

E1 1 ANTALIS PATRICIA LYNN/AU

E2 19 ANTALIS T/AU

E3 204 --> ANTALIS T M/AU

E4 1 ANTALIS T M */AU

E5 9 ANTALIS TONI/AU

E6 99 ANTALIS TONI M/AU

E7	6	ANTALIS TONI MARIE/AU
E8	1	ANTALK ISTVAN/AU
E9	5	ANTALKI T/AU
E10	1	ANTALL GLORIA F/AU
E11	40	ANTALL J/AU
E12	1	ANTALL K L/AU

=> s e3

L6 204 "ANTALIS T M"/AU

=> e hooper j d/au

E1	17	HOOPER J B/AU
E2	29	HOOPER J C/AU
E3	89 -->	HOOPER J D/AU
E4	1	HOOPER J D H/AU
E5	193	HOOPER J E/AU
E6	1	HOOPER J E */AU
E7	1	HOOPER J E N/AU
E8	53	HOOPER J F/AU
E9	1	HOOPER J F G/AU
E10	3	HOOPER J G/AU
E11	1	HOOPER J G V/AU
E12	20	HOOPER J H/AU

=> s e3

L7 89 "HOOPER J D"/AU

=> d his

(FILE 'HOME' ENTERED AT 15:40:36 ON 14 NOV 2006)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 15:41:25 ON 14 NOV 2006

L1	38020	S SERINE (W) PROTEINASE?
L2	8014433	S CLON? OR EXPRESS? OR RECOMBINANT
L3	12818	S L1 AND L2
L4	6935	S HUMAN AND L3
L5	0	S E ANTALIS T M/AU
		E ANTALIS T M/AU
L6	204	S E3
		E HOOPER J D/AU
L7	89	S E3

=> s 16 or 17

L8 268 L6 OR L7

=> s 14 and 18

L9 38 L4 AND L8

=> dup rem 19

PROCESSING COMPLETED FOR L9

L10 26 DUP REM L9 (12 DUPLICATES REMOVED)

=> d 1-26 ibib ab

L10 ANSWER 1 OF 26 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2005132003 EMBASE

TITLE: Silencing of integrated human papillomavirus type 18 oncogene transcription in cells expressing SerpinB2.

AUTHOR: Darnell G.A.; Antalis T.M.; Rose B.R.; Suhrbier A.

CORPORATE SOURCE: A. Suhrbier, Queensland Inst. of Medical Research, Post

Office Royal Brisbane Hospital, Brisbane, QLD 4029,
Australia. andreasS@qimr.edu.au

SOURCE: Journal of Virology, (2005) Vol. 79, No. 7, pp. 4246-4256.

Refs: 61
ISSN: 0022-538X CODEN: JOVIAM

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 004 Microbiology

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 7 Apr 2005
Last Updated on STN: 7 Apr 2005

AB The serine protease inhibitor SerpinB2 (PAI-2), a major product of differentiating squamous epithelial cells, has recently been shown to bind and protect the retinoblastoma protein (Rb) from degradation. In human papillomavirus type 18 (HPV-18)-transformed epithelial cells the expression of the E6 and E7 oncoproteins is controlled by the HPV-18 upstream regulatory region (URR). Here we illustrate that PAI-2 expression in the HPV-18-transformed cervical carcinoma line HeLa resulted in the restoration of Rb expression, which led to the functional silencing of transcription from the HPV-18 URR. This caused loss of E7 protein expression and restoration of multiple E6- and E7-targeted host proteins, including p53, c-Myc, and c-Jun. Rb expression emerged as sufficient for the transcriptional repression of the URR, with repression mediated via the C/EBP β -YY1 binding site (URR 7709 to 7719). In contrast to HeLa cells, where the C/EBP β -YY1 dimer binds this site, in PAI-2- and/or Rb-expressing cells the site was occupied by the dominant-negative C/EBP β isoform liver-enriched transcriptional inhibitory protein (LIP). PAI-2 expression thus has a potent suppressive effect on HPV-18 oncogene transcription mediated by Rb and LIP, a finding with potential implications for prognosis and treatment of HPV-transformed lesions. Copyright .COPYRG. 2005, American Society for Microbiology. All Rights Reserved.

L10 ANSWER 2 OF 26 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2005150054 EMBASE

TITLE: Hypermethylation of the 5' CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis.

AUTHOR: Manton K.J.; Douglas M.L.; Netzel-Arnett S.; Fitzpatrick D.R.; Nicol D.L.; Boyd A.W.; Clements J.A.; Antalis T.M.

CORPORATE SOURCE: Dr. T.M. Antalis, Department of Physiology, Univ. of Maryland School of Medicine, 15601 Crabbs Branch Way, Rockville, MD 20855, Australia. tantalis@som.umaryland.edu

SOURCE: British Journal of Cancer, (28 Feb 2005) Vol. 92, No. 4, pp. 760-769. .
Refs: 62
ISSN: 0007-0920 CODEN: BJCAAI

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 016 Cancer
022 Human Genetics
028 Urology and Nephrology

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 28 Apr 2005
Last Updated on STN: 28 Apr 2005

AB The Testisin gene (PRSS21) encodes a glycosylphosphatidylinositol (GPI)-linked serine protease that exhibits testis tissue-specific expression. Loss of Testisin has been implicated in testicular

tumorigenesis, but its role in testis biology and tumorigenesis is not known. Here we have investigated the role of CpG methylation in Testisin gene inactivation and tested the hypothesis that Testisin may act as a tumour suppressor for testicular tumorigenesis. Using sequence analysis of bisulphite-treated genomic DNA, we find a strong relationship between hypermethylation of a 385 bp 5' CpG rich island of the Testisin gene, and silencing of the Testisin gene in a range of human tumour cell lines and in 100% (eight/eight) of testicular germ cell tumours. We show that treatment of Testisin-negative cell lines with demethylating agents and/or a histone deacetylase inhibitor results in reactivation of Testisin gene expression, implicating hypermethylation in Testisin gene silencing. Stable expression of Testisin in the Testisin-negative Tera-2 testicular cancer line suppressed tumorigenicity as revealed by inhibition of both anchorage-dependent cell growth and tumour formation in an SCID mouse model of testicular tumorigenesis. Together these data show that loss of Testisin is caused, at least in part, by DNA hypermethylation and histone deacetylation, and suggest a tumour suppressor role for Testisin in testicular tumorigenesis. .COPYRGT. 2005 Cancer Research UK.

L10 ANSWER 3 OF 26 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2005160787 EMBASE
 TITLE: Amalfi to Washington D.C. - Twenty years of plasminogen activator research.
 AUTHOR: Antalis T.M.; Bugge T.H.; Lawrence D.A.;
 Netzel-Arnett S.; Schwartz B.S.; Strickland D.K.
 CORPORATE SOURCE: T.H. Bugge, National Institutes of Health, Oral and
 Pharyngeal Branch, 30 Convent Drive, Bethesda, MD 20852,
 United States. thomas.bugge@nih.gov
 SOURCE: Thrombosis and Haemostasis, (2005) Vol. 93, No. 4, pp.
 625-626. .
 Refs: 7
 ISSN: 0340-6245 CODEN: THHADQ
 COUNTRY: Germany
 DOCUMENT TYPE: Journal; Editorial
 FILE SEGMENT: 008 Neurology and Neurosurgery
 016 Cancer
 018 Cardiovascular Diseases and Cardiovascular Surgery
 025 Hematology
 029 Clinical Biochemistry
 037 Drug Literature Index
 LANGUAGE: English
 ENTRY DATE: Entered STN: 28 Apr 2005
 Last Updated on STN: 28 Apr 2005

L10 ANSWER 4 OF 26 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2005384070 EMBASE
 TITLE: Malriptide-3 is a novel phylogenetically preserved
 membrane-anchored serine protease with broad serpin
 reactivity.
 AUTHOR: Szabo R.; Netzel-Arnett S.; Hobson J.P.; Antalis
 T.M.; Bugge T.H.
 CORPORATE SOURCE: T.H. Bugge, Proteases and Tissue Remodeling Unit, National
 Institute of Dental and Craniofacial Research, National
 Institutes of Health, 30 Convent Drive, Bethesda, MD 20892,
 United States. thomas.bugge@nih.gov
 SOURCE: Biochemical Journal, (15 Aug 2005) Vol. 390, No. 1, pp.
 231-242. .
 Refs: 48
 ISSN: 0264-6021 CODEN: BIJOAK
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 15 Sep 2005
Last Updated on STN: 15 Sep 2005

AB We report in the present study the bioinformatic identification, molecular cloning and biological characterization of matriptase-3, a novel membrane-anchored serine protease that is phylogenetically preserved in fish, birds, rodents, canines and primates. The gene encoding matriptase-3 is located on syntenic regions of human chromosome 3q13.2, mouse chromosome 16B5, rat chromosome 11q21 and chicken chromosome 1. Bioinformatic analysis combined with cDNA cloning predicts a functional TTSP (type II transmembrane serine protease) with 31% amino acid identity with both matriptase/MT-SP1 and matriptase-2. This novel protease is composed of a short N-terminal cytoplasmic region followed by a transmembrane domain, a stem region with one SEA, two CUB and three LDLRa (low-density lipoprotein receptor domain class A) domains and a C-terminal catalytic serine protease domain. Transcript analysis revealed restricted, species-conserved expression of matriptase-3, with the highest mRNA levels in brain, skin, reproductive and oropharyngeal tissues. The full-length matriptase-3 cDNA directed the expression of a 90 kDa N-glycosylated protein that localized to the cell surface, as assessed by cell-surface biotin labelling. The purified activated matriptase-3 serine protease domain expressed in insect cells hydrolysed synthetic peptide substrates, with a strong preference for Arg at position P(1), and showed proteolytic activity towards several macromolecular substrates, including gelatin, casein and albumin. Interestingly, activated matriptase-3 formed stable inhibitor complexes with an array of serpins, including plasminogen activator inhibitor-1, protein C inhibitor, α 1-proteinase inhibitor, α 2-antiplasmin and antithrombin III. Our study identifies matriptase-3 as a novel biologically active TTSP of the matriptase subfamily having a unique expression pattern and post-translational regulation. .COPYRG. 2005 Biochemical Society.

L10 ANSWER 5 OF 26 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004495541 EMBASE
TITLE: Mouse DESC1 is located within a cluster of seven DESC1-like genes and encodes a type II transmembrane serine protease that forms serpin inhibitory complexes.
AUTHOR: Hobson J.P.; Netzel-Arnett S.; Szabo R.; Rehault S.M.; Church F.C.; Strickland D.K.; Lawrence D.A.; Antalís T.M.; Bugge T.H.
CORPORATE SOURCE: T.H. Bugge, Proteases and Tissue Remodeling Unit, Oral and Pharyngeal Cancer Branch, National Institutes of Health, 30 Convent Dr., Bethesda, MD 20892, United States. thomas.bugge@nih.gov
SOURCE: Journal of Biological Chemistry, (5 Nov 2004) Vol. 279, No. 45, pp. 46981-46994. .
Refs: 62
ISSN: 0021-9258 CODEN: JBCHA3
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 016 Cancer
029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 28 Dec 2004
Last Updated on STN: 28 Dec 2004

AB We report the identification and functional analysis of a type II transmembrane serine protease encoded by the mouse differentially expressed in squamous cell carcinoma (DESC) 1 gene, and the definition of a cluster of seven homologous DESC1-like genes within a

0.5-Mb region of mouse chromosome 5E1. This locus is syntenic to a region of human chromosome 4q13.3 containing the human orthologues of four of the mouse DESC1-like genes. Bioinformatic analysis indicated that all seven DESC1-like genes encode functional proteases. Direct cDNA cloning showed that mouse DESC1 encodes a multidomain serine protease with an N-terminal signal anchor, a SEA (sea urchin sperm protein, enterokinase, and agrin) domain, and a C-terminal serine protease domain. The mouse DESC1 mRNA was present in epidermal, oral, and male reproductive tissues and directed the translation of a membrane-associated 60-kDa N-glycosylated protein with type II topology. Mouse DESC1 was synthesized in insect cells as a zymogen that could be activated by exposure to trypsin. The purified activated DESC1 hydrolyzed synthetic peptide substrates, showing a preference for Arg in the P(1) position. DESC1 proteolytic activity was abolished by generic inhibitors of serine proteases but not by other classes of protease inhibitors. Most interestingly, DESC1 formed stable inhibitory complexes with both plasminogen activator inhibitor-1 and protein C inhibitor that are expressed in the same tissues with DESC1, suggesting that type II transmembrane serine proteases may be novel targets for serpin inhibition. Together, these data show that mouse DESC1 encodes a functional cell surface serine protease that may have important functions in the epidermis, oral, and reproductive epithelium.

L10 ANSWER 6 OF 26 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004034771 EMBASE
 TITLE: Serpin mutagenesis.
 AUTHOR: Antalis T.M.; Lawrence D.A.
 CORPORATE SOURCE: T.M. Antalis, Department of Vascular Biology, Jerome H. Holland Lab. Biomed. Sci., American Red Cross, Rockville, MD 20855, United States. antalist@usa.redcross.org
 SOURCE: Methods, (2004) Vol. 32, No. 2, pp. 130-140. .
 Refs: 68
 ISSN: 1046-2023 CODEN: MTHDE
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 029 Clinical Biochemistry
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 12 Feb 2004
 Last Updated on STN: 12 Feb 2004

AB Mutagenesis represents a powerful methodology for the analysis of protein structural and functional relationships and dissection of complex protein-protein interactions. The suicide substrate-like inhibitory mechanism of the proteins of the serpin superfamily offers unique challenges for the design of mutagenesis studies. All serpins share a well-characterized core structure and most adopt a metastable conformation that is required for inhibitory activity. Mutagenesis studies focused on the reactive center loop, the hinge region, protease-binding exo-sites, conformational stability, and accessory ligand binding domains have led to a well-established serpin inhibitory mechanism and have defined specific biological interactions and functions for a number of serpins in development, homeostasis, and host defense. Nonetheless, great care must be taken in the design and interpretation of serpin mutagenesis studies, since the rapid conformational changes that occur during serpin inhibition can be affected at many levels. .COPYRGHT. 2003 Elsevier Inc. All rights reserved.

L10 ANSWER 7 OF 26 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 1

ACCESSION NUMBER: 2003360166 EMBASE
 TITLE: Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif.

AUTHOR: Darnell G.A.; Antalis T.M.; Johnstone R.W.;
 Stringer B.W.; Ogbourne S.M.; Harrich D.; Suhrbier A.
 CORPORATE SOURCE: A. Suhrbier, Queensland Inst. of Medical Research, 300
 Herston Rd., Herston, QLD 4029, Canada.
 andreass@gimr.edu.au
 SOURCE: Molecular and Cellular Biology, (2003) Vol. 23, No. 18, pp.
 6520-6532. .
 Refs: 55
 ISSN: 0270-7306 CODEN: MCEBD4
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 016 Cancer
 029 Clinical Biochemistry
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 2 Oct 2003
 Last Updated on STN: 2 Oct 2003

AB Plasminogen activator inhibitor-2 (PAI-2) is well documented as an
 inhibitor of the extracellular serine proteinase
 urokinase-type plasminogen activator (uPA) and is expressed in
 activated monocytes and macrophages, differentiating keratinocytes, and
 many tumors. Here we show that PAI-2 has a novel intracellular function
 as a retinoblastoma protein (Rb)-binding protein. PAI-2 colocalized with
 Rb in the nucleus and inhibited the turnover of Rb, which led to increases
 in Rb protein levels and Rb-mediated activities. Although PAI-2 contains
 an LXCXE motif, Rb binding was primarily mediated by the C-D interhelical
 region of PAI-2, which was found to bind to the C pocket of Rb. The C-D
 interhelical region of PAI-2 contained a novel Rb-binding motif, termed
 the PENF homology motif, which is shared by many cellular and viral
 Rb-binding proteins. PAI-2 expression also protected Rb from
 the accelerated degradation mediated by human papillomavirus
 (HPV) E7, leading to recovery of Rb and inhibition of E6/E7 mRNA
 expression. Protection of Rb by PAI-2 begins to explain many of
 the diverse, uPA-independent phenotypes conferred by PAI-2
 expression. These results indicate that PAI-2 may enhance Rb's
 tumor suppressor activity and suggest a potential therapeutic role for
 PAI-2 against HPV-transformed lesions.

L10 ANSWER 8 OF 26 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
 reserved on STN

ACCESSION NUMBER: 2003329749 EMBASE
 TITLE: Mouse matriptase-2: Identification, characterization and
 comparative mRNA expression analysis with mouse
 hepsin in adult and embryonic tissues.
 AUTHOR: Hooper J.D.; Campagnolo L.; Goodarzi G.; Truong
 T.N.; Stuhlmann H.; Quigley J.P.
 CORPORATE SOURCE: J.P. Quigley, Division of Vascular Biology, Department of
 Cell Biology, Scripps Research Institute, 10550 North
 Torrey Pines Road, San Diego, CA 92037, United States.
 jquigley@scripps.edu
 SOURCE: Biochemical Journal, (1 Aug 2003) Vol. 373, No. 3, pp.
 689-702. .
 Refs: 59
 ISSN: 0264-6021 CODEN: BIJOAK
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 029 Clinical Biochemistry
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 4 Sep 2003
 Last Updated on STN: 4 Sep 2003

AB We report the identification and characterization of mouse matriptase-2
 (m-matriptase-2), an 811-amino-acid protein composed of an N-terminal
 cytoplasmic domain, a membrane-spanning domain, two CUB (complement

protein subcomponents C1r/C1s, urchin embryonic growth factor and bone morphogenetic protein 1) domains, three LDLR (low-density-lipoprotein receptor class A) domains and a C-terminal serine-protease domain. All m-matriptase-2 protein domain boundaries corresponded with intron/exon junctions of the encoding gene, which spans approx. 29 kb and comprises 18 exons. Matriptase-2 is highly conserved in human, mouse and rat, with the rat matriptase-2 gene (r-matriptase-2) predicted to encode transmembrane and soluble isoforms. Western-blot analysis indicated that m-matriptase-2 migrates close to its theoretical molecular mass of 91 kDa, and immunofluorescence analysis was consistent with the proposed surface membrane localization of this protein. Reverse-transcription PCR and in-situ-hybridization analysis indicated that m-matriptase-2 expression overlaps with the distribution of mouse hepsin (m-hepsin, a cell-surface serine protease identified in hepatoma cells) in adult tissues and during embryonic development. In adult tissues both are expressed at highest levels in liver, kidney and uterus. During embryogenesis m-matriptase-2 expression peaked between days 12.5 and 15.5. m-hepsin expression was biphasic, with peaks at day 7.5 to 8.5 and again between days 12.5 and 15.5. In situ hybridization of embryonic tissues indicated abundant expression of both m-matriptase-2 and m-hepsin in the developing liver and at lower levels in developing pharyngo-tympanic tubes. While m-hepsin was detected in the residual embryonic yolk sac and with lower intensity in lung, heart, gastrointestinal tract, developing kidney tubules and epithelium of the oral cavity, m-matriptase-2 was absent in these tissues, but strongly expressed within the nasal cavity by olfactory epithelial cells. Mechanistic insight into the potential role of this new transmembrane serine protease is provided by its novel expression profile in embryonic and adult mouse.

L10 ANSWER 9 OF 26 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003117808 EMBASE
 TITLE: Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis.
 AUTHOR: Aimes R.T.; Zijlstra A.; Hooper J.D.; Ogbourne S.M.; Sit M.-L.; Fuchs S.; Gotley D.C.; Quigley J.P.; Antalis T.M.
 CORPORATE SOURCE: T.M. Antalis, Department of Vascular Biology, Jerome H. Holland Laboratory, American Red Cross, 15601 Crabbs Branch Way, Rockville, MD 20855, United States. antalist@usa.redcross.org
 SOURCE: Thrombosis and Haemostasis, (1 Mar 2003) Vol. 89, No. 3, pp. 561-572. .
 Refs: 78
 ISSN: 0340-6245 CODEN: THHADQ
 COUNTRY: Germany
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 022 Human Genetics
 018 Cardiovascular Diseases and Cardiovascular Surgery
 025 Hematology
 029 Clinical Biochemistry
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 3 Apr 2003
 Last Updated on STN: 3 Apr 2003

AB Many serine proteases play important regulatory roles in complex biological systems, but only a few have been linked directly with capillary morphogenesis and angiogenesis. Here we provide evidence that serine protease activities, independent of the plasminogen activation cascade, are required for microvascular endothelial cell reorganization and capillary morphogenesis in vitro. A homology cloning approach targeting conserved motifs present in all serine proteases, was used to identify candidate serine proteases involved in these processes,

and revealed 5 genes (acrosin, testisin, neurosin, PSP and neurotrypsin), none of which had been associated previously with expression in endothelial cells. A subsequent gene-specific RT-PCR screen for 22 serine proteases confirmed expression of these 5 genes and identified 7 additional serine protease genes expressed by human endothelial cells, urokinase-type plasminogen activator, protein C, TMPRSS2, hepsin, matriptase/MT-SPI, dipeptidylpeptidase IV, and seprase. Differences in serine protease gene expression between microvascular and human umbilical vein endothelial cells (HUVECs) were identified and several serine protease genes were found to be regulated by the nature of the substratum, ie. artificial basement membrane or fibrillar type I collagen. mRNA transcripts of several serine protease genes were associated with blood vessels in vivo by in situ hybridization of human tissue specimens. These data suggest a potential role for serine proteases, not previously associated with endothelium, in vascular function and angiogenesis.

L10 ANSWER 10 OF 26 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003193798 EMBASE

TITLE: Membrane anchored serine proteases: A rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer.

AUTHOR: Netzel-Arnett S.; Hooper J.D.; Szabo R.; Madison E.L.; Quigley J.P.; Bugge T.H.; Antalis T.M.

CORPORATE SOURCE: United States. antalist@usa.redcross.org

SOURCE: Cancer and Metastasis Reviews, (2003) Vol. 22, No. 2-3, pp. 237-258.
Refs: 146

ISSN: 0167-7659 CODEN: CMRED4

COUNTRY: Netherlands

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 005 General Pathology and Pathological Anatomy
016 Cancer
029 Clinical Biochemistry

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 29 May 2003

Last Updated on STN: 29 May 2003

AB Dysregulated proteolysis is a hallmark of cancer. Malignant cells require a range of proteolytic activities to enable growth, survival, and expansion. Serine proteases of the S1 or trypsin-like family have well recognized roles in the maintenance of normal homeostasis as well as in the pathology of diseases such as cancer. Recently a rapidly expanding subgroup of S1 proteases has been recognized that are directly anchored to plasma membranes. These membrane anchored serine proteases are anchored either via a carboxy-terminal transmembrane domain (Type I), a carboxy terminal hydrophobic region that functions as a signal for membrane attachment via a glycosyl-phosphatidylinositol linkage (GPI-anchored), or via an amino terminal proximal transmembrane domain (Type II or TTSP). The TTSPs also encode multiple domains in their stem regions that may function in regulatory interactions. The serine protease catalytic domains of these enzymes show high homology but also possess features indicating unique substrate specificities. It is likely that the membrane anchored serine proteases have evolved to perform complex functions in the regulation of cellular signaling events at the plasma membrane and within the extracellular matrix. Disruption or mutation of several of the genes encoding these proteases are associated with disease. Many of the membrane anchored serine proteases show restricted tissue distribution in normal cells, but their expression is widely dysregulated during tumor growth and progression. Diagnostic or therapeutic targeting of the membrane anchored serine proteases has potential as promising new approaches for the treatment of cancer and other diseases.

L10 ANSWER 11 OF 26 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003332585 EMBASE
TITLE: Type II transmembrane serine proteases.
AUTHOR: Szabo R.; Wu Q.; Dickson R.B.; Netzel-Arnett S.;
Antalis T.M.; Bugge T.H.
CORPORATE SOURCE: Dr. T.H. Bugge, Oral and Pharyngeal Cancer Branch, Natl.
Inst. of Dent./Craniofac. Res., National Institutes of
Health, 30 Convent Drive, Bethesda, MD 20892, United
States. thomas.bugge@nih.gov
SOURCE: Thrombosis and Haemostasis, (1 Aug 2003) Vol. 90, No. 2,
pp. 185-193. .
Refs: 81
ISSN: 0340-6245 CODEN: THHADQ
COUNTRY: Germany
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 025 Hematology
029 Clinical Biochemistry
022 Human Genetics
005 General Pathology and Pathological Anatomy
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 4 Sep 2003
Last Updated on STN: 4 Sep 2003

AB The recent availability of human and mouse genome sequences and expressed sequence tag databases facilitated the identification of a large new family of membrane anchored serine proteases, the type II transmembrane serine proteases or TTSPs. Analyses of human inherited disorders and gene targeting studies in mice have revealed that several members of this new protease family have critical functions in development and health. Preliminary studies also suggest that aberrant expression of type II transmembrane serine proteases may be linked to disease progression. The knowledge gathered thus far of the genetics, physiology, and pathology of this interesting new serine protease family will be reviewed here in brief.

L10 ANSWER 12 OF 26 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 2

ACCESSION NUMBER: 2001364382 EMBASE
TITLE: Characterisation of PAUSE-1, a powerful silencer in the human plasminogen activator inhibitor type 2 gene promoter.
AUTHOR: Ogbourne S.M.; Antalis T.M.
CORPORATE SOURCE: T.M. Antalis, Department of Vascular Biology, Holland Laboratory, American Red Cross, 15601 Crabbs Branch Way, Rockville, MD 20855, United States.
antalist@usa.redcross.org
SOURCE: Nucleic Acids Research, (1 Oct 2001) Vol. 29, No. 19, pp. 3919-3927. .
Refs: 39
ISSN: 0305-1048 CODEN: NARHAD
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 022 Human Genetics
029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 2 Nov 2001
Last Updated on STN: 2 Nov 2001

AB Plasminogen activator inhibitor type 2 (PAI-2) is a serine protease inhibitor traditionally regarded as a regulator of fibrinolysis and extracellular matrix degradation. More recently, PAI-2 has been implicated in diverse processes such as keratinocyte differentiation, cell death and viral pathogenesis. The PAI-2 promoter tightly regulates PAI-2

gene expression in a cell-specific manner and this control is mediated, in part, by the upstream silencer element, PAUSE-1. Here we have defined PAUSE-1 and investigated its activity as a silencer. A series of mutations were generated within the PAUSE-1 element and analysed for transcription factor binding and transcriptional silencing activity. These studies have defined the minimal functional PAUSE-1 element as TCTN(x)AGAN(3)T(4), where x = 0, 2 or 4. Examination of related elements present in other promoters, such as the human IFN β promoter, suggests that PAUSE-1 is a member of a family of universal silencers with the consensus sequence TCTN(x)AGA. UV crosslinking analyses determined that the PAUSE-1 binding protein was .apprx.67 kDa. Insertion of PAUSE-1 into the heterologous (SV40) or the minimal PAI-2 promoters silenced transcription by 2.5-fold. These data show that PAUSE-1 acts as a powerful silencer of PAI-2 gene transcription and is likely to be important in the silencing of other genes as well.

L10 ANSWER 13 OF 26 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 3

ACCESSION NUMBER: 2001160112 EMBASE
 TITLE: Identification and characterization of KLK14, a novel kallikrein serine protease gene located on human chromosome 19q13.4 and expressed in prostate and skeletal muscle.
 AUTHOR: Hooper J.D.; Bui L.T.; Rae F.K.; Harvey T.J.; Myers S.A.; Ashworth L.K.; Clements J.A.
 CORPORATE SOURCE: J.A. Clements, Centre for Molecular Biotechnology, School of Life Sciences, Queensland University of Technology, GPO Box 2434, Brisbane, QLD 4001, Australia. j.clements@qut.edu.au.
 SOURCE: Genomics, (1 Apr 2001) Vol. 73, No. 1, pp. 117-122. . Refs: 22
 ISSN: 0888-7543 CODEN: GNMCEP
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 022 Human Genetics
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 17 May 2001
 Last Updated on STN: 17 May 2001

AB The kallikreins are a subfamily of serine proteases encoded in human, mouse, and rat by highly conserved tightly clustered multigene families. Here we report the identification and characterization of KLK14, a novel kallikrein gene located within the human kallikrein locus at 19q13.4. KLK14 is approximately 5.4 kb in length spanning seven exons and, by Northern blot analysis, transcribes two alternative transcripts present only in prostate (1.5 kb) and skeletal muscle (1.9 kb). The protein product, K14, predicted to be a 251-amino-acid secreted serine protease with trypsin-like substrate specificity, is translated in vitro with a molecular mass of .apprx.31 kDa. In situ hybridization revealed that, in prostate, KLK14 is expressed by both benign and malignant glandular epithelial cells, thus exhibiting an expression pattern similar to that of two other prostatic kallikreins, KLK2 and KLK3, which encode K2 and prostate-specific antigen, respectively. .COPYRGT. 2001 Academic Press.

L10 ANSWER 14 OF 26 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2001214239 EMBASE
 TITLE: Human trypsinogen in colorectal cancer.
 AUTHOR: Williams S.J.; Gotley D.C.; Antalis T.M.
 CORPORATE SOURCE: T.M. Antalis, Queensland Inst. of Medical Research, Post Office Royal Brisbane Hospital, Brisbane, QLD 4029, Australia. toniA@qimr.edu.au
 SOURCE: International Journal of Cancer, (1 Jul 2001) Vol. 93, No.

1, pp. 67-73. .
Refs: 43
ISSN: 0020-7136 CODEN: IJCNAW

COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 016 Cancer
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 10 Jul 2001

Last Updated on STN: 10 Jul 2001

AB Trypsinogen (TRY), the precursor to the serine protease trypsin, is found in the pancreas and mediates digestive proteolysis in the small intestine. Differential display of cDNAs expressed by human colorectal tumor tissues compared with adjacent normal colonic mucosa identified an isoform of TRY (TRY2) up-regulated in colorectal cancers. Northern blot analysis of RNA isolated from a series of 28 malignant colon tumors and corresponding normal mucosa showed that TRY transcripts were up-regulated 2- to 33-fold in 29% of tumors. Further, TRY mRNA was expressed in 6 colorectal cancer cell lines, with highest levels detected in the metastatic tumor lines SW620 and HT29. Immunostaining for TRY protein expression showed intense immunoreactivity in the supranuclear cytoplasm of colon tumors in 16% of tissue specimens. To evaluate the relative contributions of 2 isoforms of TRY, TRY1 and TRY2, to total TRY mRNA expression, a semi-quantitative multiplex RT-PCR assay was developed. TRY2 mRNA was detected in all 6 colorectal tumor cell lines, whereas TRY1 mRNA was expressed only in the metastatic tumor lines, showing that the high levels of TRY expression in the metastatic tumor lines are likely due to up-regulation of TRY1. Evaluation of TRY1 and TRY2 mRNA expression by multiplex RT-PCR in a series of 20 colon tumor tissues representative of the range of tumor progression showed that TRY2 mRNA was expressed much more commonly than TRY1 mRNA in normal mucosa (26% vs. 6%) as well as in primary tumor tissues (65% vs. 15%). These data demonstrate that TRY2 is the dominant TRY in colon tissue and suggest that up-regulation of TRY1 expression in colon tumors may be associated with a metastatic phenotype. .COPYRG. 2001 Wiley-Liss, Inc.

L10 ANSWER 15 OF 26 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2001003284 EMBASE
TITLE: Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4.
AUTHOR: Harvey T.J.; Hooper J.D.; Myers S.A.; Stephenson S.A.; Ashworth L.K.; Clements J.A.
CORPORATE SOURCE: J.A. Clements, Centre for Molecular Biotechnology, School of Life Sciences, Queensland University of Technology, GPO Box 2434, Brisbane, QLD 4001, Australia.
SOURCE: j.clements@qut.edu.au
Journal of Biological Chemistry, (1 Dec 2000) Vol. 275, No. 48, pp. 37397-37406. .

Refs: 50
ISSN: 0021-9258 CODEN: JBCHA3

COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 022 Human Genetics
029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 11 Jan 2001

Last Updated on STN: 11 Jan 2001

AB The tissue or glandular kallikreins (KLK) are members of a highly conserved multigene family encoding serine proteases that are central to

many biological processes. The rodent KLK families are large, highly conserved and clustered at one locus. The human KLK gene family is clustered on chromosome 19q13.3-13.4, and until recently consisted of just three members. However, recent studies have identified up to 11 new members of the KLK family that are less conserved than their rodent counterparts. Using a Southern blot and sequence analysis of 10 BACs and cosmids spanning approximately 400 kilobases (kb) either side of the original KLK 60-kb locus, we demonstrated that these genes also lie adjacent to this. We have also clarified the position of several microsatellite markers in relation to the extended KLK locus. Moreover, from Southern blot analysis of the cosmids and BACs with a degenerate oligonucleotide probe to the histidine-encoding region of serine proteases, we have shown that there are no other serine protease genes approximately 400 kb centromeric and 220 kb telomeric of the extended locus. We performed an extensive analysis of the expression patterns of these genes by poly(A)(+) RNA dot blot and reverse transcriptase-polymerase chain reaction analysis, and demonstrated a diverse pattern of expression. Of interest are clusters of genes with high prostate (KLK2-4) and pancreatic (KLK6-13) expression suggesting evolutionary conservation of elements conferring tissue specificity. From these findings, it is likely that the human KLK gene family consists of just 14 clustered genes within 300 kb and thus is of a comparable size to the rodent families (13-24 genes within 310 and 480 kb, respectively). In contrast to the rodent families, the newest members of the human KLK family are much less conserved in sequence (23-44% at the protein level) and appear to consist of at least four subfamilies. In addition, like the rat, these genes are expressed at varying levels in a diverse range of tissues although they exhibit quite distinct patterns of expression.

L10 ANSWER 16 OF 26 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2000414737 EMBASE
 TITLE: Localization of the mosaic transmembrane serine protease corin to heart myocytes.
 AUTHOR: Hooper J.D.; Scarman A.L.; Clarke B.E.; Normyle J.F.; Antalis T.M.
 CORPORATE SOURCE: T.M. Antalis, Queensland Inst. of Med. Research, Post Office Royal Brisbane Hospital, Brisbane, QLD 4029, Australia. toniA@qimr.edu.au
 SOURCE: European Journal of Biochemistry, (2000) Vol. 267, No. 23, pp. 6931-6937. .
 Refs: 33
 ISSN: 0014-2956 CODEN: EJBACI
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 018 Cardiovascular Diseases and Cardiovascular Surgery
 029 Clinical Biochemistry
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 14 Dec 2000
 Last Updated on STN: 14 Dec 2000
 AB Corin cDNA encodes an unusual mosaic type II transmembrane serine protease, which possesses, in addition to a trypsin-like serine protease domain, two frizzled domains, eight low-density lipoprotein (LDL) receptor domains, a scavenger receptor domain, as well as an intracellular cytoplasmic domain. In in vitro experiments, recombinant human corin has recently been shown to activate pro-atrial natriuretic peptide (ANP), a cardiac hormone essential for the regulation of blood pressure. Here we report the first characterization of corin protein expression in heart tissue. We generated antibodies to two different peptides derived from unique regions of the corin polypeptide, which detected immunoreactive corin protein of approximately

125-135 kDa in lysates from human heart tissues. Immunostaining of sections of human heart showed corin expression was specifically localized to the cross striations of cardiac myocytes, with a pattern of expression consistent with an integral membrane localization. Corin was not detected in sections of skeletal or smooth muscle. Corin has been suggested to be a candidate gene for the rare congenital heart disease, total anomalous pulmonary venous return (TAPVR) as the corin gene colocalizes to the TAPVR locus on human chromosome 4. However examination of corin protein expression in TAPVR heart tissue did not show evidence of abnormal corin expression. The demonstrated corin protein expression by heart myocytes supports its proposed role as the pro-ANP convertase, and thus a potentially critical mediator of major cardiovascular diseases including hypertension and congestive heart failure.

L10 ANSWER 17 OF 26 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2000201056 EMBASE

TITLE: Localization, expression and genomic structure of the gene encoding the human serine protease testisin.

AUTHOR: Hooper J.D.; Bowen N.; Marshall H.; Cullen L.M.; Sood R.; Daniels R.; Stuttgen M.A.; Normyle J.F.; Higgs D.R.; Kastner D.L.; Ogbourne S.M.; Pera M.F.; Jazwinska E.C.; Antalis T.M.

CORPORATE SOURCE: T.M. Antalis, Cellular Oncology Laboratory, Queensland Inst. Med. Research, University of Queensland, Brisbane, QLD 4029, Australia. toniA@qimr.edu.au

SOURCE: Biochimica et Biophysica Acta - Gene Structure and Expression, (21 Jun 2000) Vol. 1492, No. 1, pp. 63-71. . Refs: 45

ISSN: 0167-4781 CODEN: BBGSD5

PUBLISHER IDENT.: S 0167-4781(00)00071-3

COUNTRY: Netherlands

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 022 Human Genetics
028 Urology and Nephrology
029 Clinical Biochemistry

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 30 Jun 2000

Last Updated on STN: 30 Jun 2000

AB Testisin is a recently identified human serine protease expressed by premeiotic testicular germ cells and is a candidate tumor suppressor for testicular cancer. Here, we report the characterization of the gene encoding testisin, designated PRSS21, and its localization on the short arm of human chromosome 16 (16p13.3) between the microsatellite marker D16S246 and the radiation hybrid breakpoint CY23HA. We have further refined the localization to cosmid 406D6 in this interval and have established that the gene is approximately 4.5 kb in length, and contains six exons and five intervening introns. The structure of PRSS21 is very similar to the human prostatin gene (PRSS8) which maps nearby on 16p11.2, suggesting that these genes may have evolved through gene duplication. Sequence analysis showed that the two known isoforms of testisin are generated by alternative pre-mRNA splicing. A major transcription initiation site was identified 97 nucleotides upstream of the testisin translation start and conforms to a consensus initiator element. The region surrounding the transcription initiation site lacks a TATA consensus sequence, but contains a CCAAT sequence and includes a CpG island. The 5'-flanking region contains several consensus response elements including Sp1, AP1 and several testis-specific elements. Analysis of testisin gene expression in tumor cell lines shows that testisin is not expressed in testicular tumor cells but is aberrantly expressed in some tumor

cell lines of non-testis origin. These data provide the basis for identifying potential genetic alterations of PRSS21 that may underlie both testicular abnormalities and tumorigenesis. Copyright (C) 2000 Elsevier Science B.V.

L10 ANSWER 18 OF 26 LIFESCI COPYRIGHT 2006 CSA on STN

ACCESSION NUMBER: 1999:99590 LIFESCI

TITLE: Picornavirus Receptor Down-Regulation by Plasminogen Activator Inhibitor Type 2

AUTHOR: Shafren, D.R.*; Gardner, J.; Mann, V.H.; Antalis, T.M.; Suhrbier, A.

CORPORATE SOURCE: Picornaviral Research Unit, Discipline of Immunology and Microbiology, Faculty of Medicine and Health Sciences, University of Newcastle, Level 3, David Maddison Clinical Sciences Building, Royal Newcastle Hospital Newcastle, New South Wales 2300, Australia; E-mail: dshafren@mail.newcastle.edu.au

SOURCE: Journal of Virology [J. Virol.], (19990900) vol. 73, no. 9, pp. 7193-7198.
ISSN: 0022-538X.

DOCUMENT TYPE: Journal

FILE SEGMENT: V

LANGUAGE: English

SUMMARY LANGUAGE: English

AB Therapeutic interference with virus-cell surface receptor interactions represents a viable antiviral strategy. Here we demonstrate that cytoplasmic expression of the serine protease inhibitor (serpin), plasminogen activator inhibitor type 2 (PAI-2) affords a high level of protection from lytic infection by multiple human picornaviruses. The antiviral action of PAI-2 was mediated primarily through transcriptional down-regulation of the following virus receptors: intercellular adhesion molecule 1 (ICAM-1, a cellular receptor for the major group of rhinoviruses), decay-accelerating factor (a cellular receptor for echoviruses and coxsackieviruses), and to a lesser extent the coxsackie-adenovirus receptor protein (a cellular receptor for group B coxsackieviruses and group C adenoviruses). Expression of related cell surface receptors, including membrane cofactor protein and the poliovirus receptor, remained unaffected. These findings suggest that PAI-2 and/or related serpins may form the basis of novel antiviral strategies against picornavirus infections and also therapeutic interventions against ICAM-1-mediated respiratory inflammation.

L10 ANSWER 19 OF 26 MEDLINE on STN

DUPLICATE 4

ACCESSION NUMBER: 1999323395 MEDLINE

DOCUMENT NUMBER: PubMed ID: 10397266

TITLE: Testisin, a new human serine proteinase expressed by premeiotic testicular germ cells and lost in testicular germ cell tumors.

AUTHOR: Hooper J D; Nicol D L; Dickinson J L; Eyre H J; Scarman A L; Normyle J F; Stuttgen M A; Douglas M L; Loveland K A; Sutherland G R; Antalis T M

CORPORATE SOURCE: Cellular Oncology Laboratory, University of Queensland Joint Oncology Program and Queensland Institute of Medical Research, Brisbane, Australia.

SOURCE: Cancer research, (1999 Jul 1) Vol. 59, No. 13, pp. 3199-205.

Journal code: 2984705R. ISSN: 0008-5472.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199907

ENTRY DATE: Entered STN: 6 Aug 1999

Last Updated on STN: 3 Mar 2000

Entered Medline: 28 Jul 1999

AB We have cloned and characterized a cDNA encoding a new human serine proteinase, testisin, that is abundantly expressed only in the testis and is lost in testicular tumors. The testisin cDNA was identified by homology cloning using degenerate primers directed at conserved sequence motifs within the catalytic regions of serine proteinases. It is 1073 nucleotides long, including 942 nucleotides of open reading frame and a 113-nucleotide 3' untranslated sequence. Northern and dot blot analyses of RNA from a range of normal human tissues revealed a 1.4-kb mRNA species that was present only in testis, which was not detected in eight of eight testicular tumors. Testisin cDNA is predicted to encode a protein of 314 amino acids, which consists of a 19-amino acid (aa) signal peptide, a 22-aa proregion, and a 273-aa catalytic domain, including a unique 17-aa COOH-terminal hydrophobic extension that is predicted to function as a membrane anchor. The deduced amino acid sequence of testisin shows 44% identity to prostasin and contains features that are typical of serine proteinases with trypsin-like substrate specificity. Antipeptide antibodies directed against the testisin polypeptide detected an immunoreactive testisin protein of Mr 35,000-39,000 in cell lysates from COS-7 cells that were transiently transfected with testisin cDNA. Immunostaining of normal testicular tissue showed that testisin was expressed in the cytoplasm and on the plasma membrane of premeiotic germ cells. No staining was detected in eight of eight germ cell-derived testicular tumors. In addition, the testisin gene was localized by fluorescence in situ hybridization to the short arm of human chromosome 16 (16p13.3), a region that has been associated with allelic imbalance and loss of heterozygosity in sporadic testicular tumors. These findings demonstrate a new cell surface serine proteinase, loss of which may have a direct or indirect role in the progression of testicular tumors of germ cell origin.

L10 ANSWER 20 OF 26 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 1999:594236 SCISEARCH

THE GENUINE ARTICLE: 222XP

TITLE: Plasminogen activator inhibitor type-2 (PAI-2) gene transcription requires a novel NF-kappa B-like transcriptional regulatory motif

AUTHOR: Mahony D; Kalionis B; Antalis T M (Reprint)

CORPORATE SOURCE: PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia (Reprint); Univ Queensland, Brisbane, Qld, Australia; Queensland Inst Med Res, Cellular Oncol Lab, Brisbane, Qld 4006, Australia; Flinders Univ S Australia, Dept Obstet & Gynaecol, Sch Med, Adelaide, SA 5001, Australia

COUNTRY OF AUTHOR: Australia

SOURCE: EUROPEAN JOURNAL OF BIOCHEMISTRY, (AUG 1999) Vol. 263, No. 3, pp. 765-772.

ISSN: 0014-2956.

PUBLISHER: BLACKWELL SCIENCE LTD, P O BOX 88, OSNEY MEAD, OXFORD OX2 ONE, OXON, ENGLAND.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 34

ENTRY DATE: Entered STN: 1999

Last Updated on STN: 1999

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Induction of human plasminogen activator inhibitor type-2 (PAI-2) gene transcription is the response of macrophages to inflammatory stimuli, such as the pleiotropic cytokine, tumour necrosis factor-alpha (TNF alpha). Here we have examined whether PAI-2 gene transcription in

response to TNF alpha may be mediated through a regulatory pathway involving the transcription factor, NF-kappa B. We have tested the function of two potential NF-kappa B-like sites present in the PAI-2 proximal promoter for responsiveness to TNF alpha using chloramphenicol acetyl transferase reporter gene deletion and mutation analyses. While no evidence was found for TNF alpha regulation of the PAI-2 gene through either of these two sites, one of the NF-kappa B-like motifs, transcriptional regulatory motif (TRM), present at position -400 was found to be essential for constitutive PAI-2 transcription, as mutation of this motif abolished basal PAI-2 promoter activity in both monocyte-like U937 cells and HT1080 fibrosarcoma cells. Competition electrophoretic mobility shift assays identified four TRM-binding proteins present in U937, HT1080 and HeLa cell extracts, which bound to this motif but were not components of the NF-kappa B regulatory complex. Expression screening of a HeLa cell cDNA library using the -400 TRM as a probe identified two cDNAs encoding partial peptides which specifically bound the TRM motif. DNA sequence analysis revealed that one cDNA was novel, and the second cDNA encoded exon 5 of the nephroblastoma overexpressed (novH) protooncogene, suggesting a new role for this peptide in gene regulation. Taken together, these findings identify a new regulatory element required for constitutive PAI-2 transcription, and identify potential DNA-binding proteins associated with this element that may play a role in PAI-2 gene regulation.

L10 ANSWER 21 OF 26 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN DUPLICATE 5

ACCESSION NUMBER: 1999:405519 BIOSIS
DOCUMENT NUMBER: PREV199900405519
TITLE: Testisin, a new human serine
proteinase expressed by premeiotic
testicular germ cells.
AUTHOR(S): Scarman, A. L. [Reprint author]; Hooper, J. D.
[Reprint author]; Normyle, J. F. [Reprint author]; Nicol,
D.; Antalis, T. M. [Reprint author]
CORPORATE SOURCE: Cellular Oncology Laboratory, Queensland Institute of
Medical Research, Brisbane, QLD, Australia
SOURCE: Biology of Reproduction, (1999) Vol. 60, No. SUPPL. 1, pp.
257. print.
Meeting Info.: Thirty-Second Annual Meeting of the Society
for the Study of Reproduction. Pullman, Washington, USA.
July 31-August 3, 1999. Society for the Study of
Reproduction.
CODEN: BIREBV. ISSN: 0006-3363.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 8 Oct 1999
Last Updated on STN: 8 Oct 1999

L10 ANSWER 22 OF 26 MEDLINE on STN

ACCESSION NUMBER: 1998270910 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9607921
TITLE: The serine proteinase inhibitor
(serpin) plasminogen activation inhibitor type 2 protects
against viral cytopathic effects by constitutive interferon
alpha/beta priming.
AUTHOR: Antalis T M; La Linn M; Donnan K; Mateo L;
Gardner J; Dickinson J L; Buttigieg K; Suhrbier A
CORPORATE SOURCE: Queensland Cancer Fund Experimental Oncology Unit, The
Queensland Institute of Medical Research, Brisbane 4029,
Australia.. toniA@qimr.edu.au
SOURCE: The Journal of experimental medicine, (1998 Jun 1) Vol.
187, No. 11, pp. 1799-811.
Journal code: 2985109R. ISSN: 0022-1007.

PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199807
ENTRY DATE: Entered STN: 13 Jul 1998
Last Updated on STN: 21 Sep 2002
Entered Medline: 1 Jul 1998

AB The serine proteinase inhibitor (serpin) plasminogen activator inhibitor type 2 (PAI-2) is well characterized as an inhibitor of extracellular urokinase-type plasminogen activator. Here we show that intracellular, but not extracellular, PAI-2 protected cells from the rapid cytopathic effects of alphavirus infection. This protection did not appear to be related to an effect on apoptosis but was associated with a PAI-2-mediated induction of constitutive low-level interferon (IFN)-alpha/beta production and IFN-stimulated gene factor 3 (ISGF3) activation, which primed the cells for rapid induction of antiviral genes. This primed phenotype was associated with a rapid development of resistance to infection by the PAI-2 transfected cells and the establishment of a persistent, productive infection. PAI-2 was also induced in macrophages in response to viral RNA suggesting that PAI-2 is a virus response gene. These observations, together with the recently demonstrated PAI-2-mediated inhibition of tumor necrosis factor-alpha induced apoptosis, (a) illustrate that PAI-2 has an additional and distinct function as an intracellular regulator of signal transduction pathway(s) and (b) demonstrate a novel activity for a eukaryotic serpin.

L10 ANSWER 23 OF 26 MEDLINE on STN DUPLICATE 6
ACCESSION NUMBER: 1998451511 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9780231
TITLE: DNase I hypersensitive sites in the 5' flanking region of the human plasminogen activator inhibitor type 2 (PAI-2) gene are associated with basal and tumor necrosis factor-alpha-induced transcription in monocytes.
AUTHOR: Mahony D; Stringer B W; Dickinson J L; Antalics T M
CORPORATE SOURCE: Queensland Cancer Fund Experimental Oncology Program, The Queensland Institute of Medical Research, Brisbane, Australia.
SOURCE: European journal of biochemistry / FEBS, (1998 Sep 15) Vol. 256, No. 3, pp. 550-9.
Journal code: 0107600. ISSN: 0014-2956.
PUB. COUNTRY: GERMANY: Germany, Federal Republic of
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: GENBANK-AF071400
ENTRY MONTH: 199811
ENTRY DATE: Entered STN: 6 Jan 1999
Last Updated on STN: 3 Mar 2000
Entered Medline: 5 Nov 1998

AB The plasminogen activator inhibitor type 2 (PAI-2) gene encodes a serine proteinase inhibitor (serpin) which is rapidly induced in response to the inflammatory cytokine, tumour necrosis factor-alpha (TNFalpha) in monocytes and macrophages. As an initial step towards understanding the molecular mechanisms underlying PAI-2 gene regulation in monocytes, we report here the analysis of the chromatin structure of 9.6 kb of 5' flanking region of the human PAI-2 gene for potential cis-acting regulatory regions using DNase I hypersensitivity mapping. Sites sensitive to DNase I were mapped in two monocytic cell lines representative of early monocytic differentiation; U937 cells, which synthesise low constitutive levels of PAI-2 that were induced following treatment with TNFalpha, and a MonoMac6 cell line which did not synthesise PAI-2 even after treatment with TNFalpha. Six DNase I hypersensitive sites (DHS) were identified; three upstream of the

transcription initiation site (DH1, DH2, DH3) and three downstream of the transcription initiation site which were contained within intron A (DH4, DH5) and the exon 2/intron B junction (DH6). Among these, one distally located DH site (DH2) disappeared in both cell lines following treatment with TNFalpha. Two DH sites (DH1, DH6) were absent in PAI-2-producing U937 cells, but were present in MonoMac6 cells, which did not produce PAI-2, indicating the possible involvement of negative regulatory elements in the suppression of PAI-2 gene expression. The results demonstrate the involvement of chromatin structure in transcriptional responsiveness of the PAI-2 gene promoter and identify several loci which may be key control regions for PAI-2 gene transcription.

L10 ANSWER 24 OF 26 MEDLINE on STN DUPLICATE 7
 ACCESSION NUMBER: 1999218572 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 10200461
 TITLE: The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF-alpha induced apoptosis.
 AUTHOR: Dickinson J L; Norris B J; Jensen P H; Antalis T M
 CORPORATE SOURCE: Queensland Cancer Fund Experimental Oncology Unit, The Queensland Institute of Medical Research, Brisbane, 4029, Australia.
 SOURCE: Cell death and differentiation, (1998 Feb) Vol. 5, No. 2, pp. 163-71.
 Journal code: 9437445. ISSN: 1350-9047.
 PUB. COUNTRY: ENGLAND: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199905
 ENTRY DATE: Entered STN: 25 May 1999
 Last Updated on STN: 25 May 1999
 Entered Medline: 7 May 1999
 AB The serine proteinase inhibitor (serpin), plasminogen activator inhibitor type 2 (PAI-2), has been reported to inhibit tumor necrosis factor-alpha (TNF) induced apoptosis. In order to begin to understand the molecular basis for this protection, we have investigated the importance of a structural domain within the PAI-2 molecule, the C-D interhelical region, in mediating the protective effect. The C-D interhelical region is a 33 amino acid insertion which is unique among serpins and has been implicated in transglutaminase catalyzed cross-linking of PAI-2 to cell membranes. We have constructed a mutant of PAI-2 wherein 23 amino acids are deleted from the C-D interhelical region generating a structure predicted to be homologous to the closely related, but non-inhibitory serpin, chicken ovalbumin. The PAI-2Delta65/87 deletion mutant retained inhibitory activity against its known serine proteinase target, urokinase-type plasminogen activator (uPA); however expression of this mutant in HeLa cells failed to protect from TNF-induced apoptosis. Analyses of the cellular distribution of PAI-2 showed that intracellular PAI-2, and not secreted or cell-surface PAI-2, was likely responsible for the observed protection from TNF-induced apoptosis. No evidence was found for specific cross-linking of PAI-2 to the plasma membrane in either control or TNF/cycloheximide treated cells. The data demonstrate that the PAI-2 C-D interhelical domain is functionally important in PAI-2 protection from TNF induced apoptosis and suggest a novel function for the C-D interhelical domain in the protective mechanism.

L10 ANSWER 25 OF 26 MEDLINE on STN DUPLICATE 8
 ACCESSION NUMBER: 96070927 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 7499264
 TITLE: Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function.

AUTHOR: Dickinson J L; Bates E J; Ferrante A; Antalis T M
CORPORATE SOURCE: Queensland Cancer Fund Experimental Oncology Unit,
Queensland Institute of Medical Research, Brisbane,
Australia.
SOURCE: The Journal of biological chemistry, (1995 Nov 17) Vol.
270, No. 46, pp. 27894-904.
Journal code: 2985121R. ISSN: 0021-9258.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199601
ENTRY DATE: Entered STN: 17 Feb 1996
Last Updated on STN: 6 Feb 1998
Entered Medline: 17 Jan 1996

AB Plasminogen activator inhibitor type 2 (PAI-2) is a serine
proteinase inhibitor or serpin that is a major product of
macrophages in response to endotoxin and inflammatory cytokines. We have
explored the role of PAI-2 in apoptotic cell death initiated by tumor
necrosis factor alpha (TNF). HeLa cells stably transfected with PAI-2
cDNA were protected from TNF-induced apoptosis, whereas cells transfected
with antisense PAI-2 cDNA, a control gene, or the plasmid vector alone
remained susceptible. The level of PAI-2 expressed by different
HeLa cell clones was inversely correlated with their sensitivity
to TNF. Loss of TNF sensitivity was not a result of loss of TNF receptor
binding. In contrast, PAI-2 expression did not confer
protection against apoptosis induced by ultraviolet or ionizing radiation.
The serine proteinase urokinase-type plasminogen
activator was not demonstrated to be the target of PAI-2 action. The
P1-Arg amino acid residue of PAI-2 was determined to be required for
protection, because cells expressing PAI-2 with an Ala in this
position were not protected from TNF-mediated cell death. The results
suggest that intracellular PAI-2 might be an important factor in
regulating cell death in TNF-mediated inflammatory processes through
inhibition of a proteinase involved in TNF-induced apoptosis.

L10 ANSWER 26 OF 26 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN

ACCESSION NUMBER: 88073947 EMBASE
DOCUMENT NUMBER: 1988073947
TITLE: Cloning and expression of a cDNA coding
for a human monocyte-derived plasminogen
activator inhibitor.
AUTHOR: Antalis T.M.; Clark M.A.; Barnes T.; Lehrbach
P.R.; Devine P.L.; Schevzov G.; Goss N.H.; Stephens R.W.;
Tolstoshev P.
CORPORATE SOURCE: Biotechnology Australia Pty. Ltd., Roseville, NSW 2069,
Australia
SOURCE: Proceedings of the National Academy of Sciences of the
United States of America, (1988) Vol. 85, No. 4, pp.
985-989.
ISSN: 0027-8424 CODEN: PNASA6
COUNTRY: United States
DOCUMENT TYPE: Journal
FILE SEGMENT: 022 Human Genetics
029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 11 Dec 1991
Last Updated on STN: 11 Dec 1991

AB Human monocyte-derived plasminogen activator inhibitor (mPAI-2)
was purified to homogeneity from the U937 cell line and partially
sequenced. Oligonucleotide probes derived from this sequence were used to
screen a cDNA library prepared from U937 cells. One positive

clone was sequenced and contained most of the coding sequence as well as a long incomplete 3' untranslated region (1112 base pairs). This cDNA sequence was shown to encode mPAI-2 by hybrid-select translation. A cDNA clone encoding the remainder of the mPAI-2 mRNA was obtained by primer extension of U937 poly(A)+ RNA using a probe complementary to the mPAI-2 coding region. The coding sequence for mPAI-2 was placed under the control of the λ P(L) promoter, and the protein expressed in Escherichia coli formed a complex with urokinase that could be detected immunologically. By nucleotide sequence analysis, mPAI-2 cDNA encodes a protein containing 415 amino acids with a predicted unglycosylated M(R) of 46,543. The predicted amino acid sequence of mPAI-2 is very similar to placental PAI-2 (3 amino acid differences) and shows extensive homology with members of the serine protease inhibitor (serpin) superfamily. mPAI-2 was found to be more homologous to ovalbumin (37%) than the endothelial plasminogen activator inhibitor, PAI-1 (26%). Like ovalbumin, mPAI-2 appears to have no typical amino-terminal signal sequence. The 3' untranslated region of the mPAI-2 cDNA contains a putative regulatory sequence that has been associated with the inflammatory mediators.

=> d his

(FILE 'HOME' ENTERED AT 15:40:36 ON 14 NOV 2006)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 15:41:25 ON 14 NOV 2006

```
L1      38020 S SERINE (W) PROTEINASE?
L2      8014433 S CLON? OR EXPRESS? OR RECOMBINANT
L3      12818 S L1 AND L2
L4      6935 S HUMAN AND L3
L5      0 S E ANTALIS T M/AU
        E ANTALIS T M/AU
L6      204 S E3
        E HOOPER J D/AU
L7      89 S E3
L8      268 S L6 OR L7
L9      38 S L4 AND L8
L10     26 DUP REM L9 (12 DUPLICATES REMOVED)
```

=> s human (w)l1

```
L11     214 HUMAN (W) L1
```

=> s l2 and l3

```
L12     12818 L2 AND L3
```

=> s l2 and l11

```
L13     129 L2 AND L11
```

=> dup rem l13

PROCESSING COMPLETED FOR L13

```
L14     85 DUP REM L13 (44 DUPLICATES REMOVED)
```

=> d 1-85 ibib

```
L14  ANSWER 1 OF 85  SCISEARCH  COPYRIGHT (c) 2006 The Thomson Corporation  on
      STN
```

ACCESSION NUMBER: 2006:232315 SCISEARCH

THE GENUINE ARTICLE: 015RQ

TITLE: A novel protease inhibitor of the alpha(2)-macroglobulin family expressed in the human epidermis

AUTHOR: Galliano M F; Toulza E; Gallinaro H; Jonca N; Ishida-Yamamoto A; Serre G; Guerrin M (Reprint)

CORPORATE SOURCE: UDEAR, UMR 5165, 37 Allees J Guesde, F-31073 Toulouse,

France (Reprint); Toulouse III Univ CHU, CNRS, INSERM, UMR 5165, F-31073 Toulouse, France; Asahikawa Med Coll, Dept Dermatol, Asahikawa, Hokkaido 0788510, Japan
mweber@udear.cnrs.fr

COUNTRY OF AUTHOR: France; Japan

SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (3 MAR 2006) Vol. 281, No. 9, pp. 5780-5789.
ISSN: 0021-9258.

PUBLISHER: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 56

ENTRY DATE: Entered STN: 9 Mar 2006
Last Updated on STN: 15 Sep 2006
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L14 ANSWER 2 OF 85 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2006:407592 BIOSIS

DOCUMENT NUMBER: PREV200600406350

TITLE: Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia.

AUTHOR(S): Haider, Asifa S.; Peters, Sara B.; Kaporis, Helen; Cardinale, Irma; Fei, Ji; Ott, Jurg; Blumenberg, Miki; Bowcock, Ann M.; Krueger, James G.; Carucci, John A.
[Reprint Author]

CORPORATE SOURCE: Weill Med Coll Cornell, Sect Mohs Microg and Dermatol Surg, Dept Dermatol, 525 E 68th St, Starr 326, New York, NY 10021 USA
JAC2015@med.cornell.edu

SOURCE: Journal of Investigative Dermatology, (APR 2006) Vol. 126, No. 4, pp. 869-881.
CODEN: JIDEAE. ISSN: 0022-202X.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 17 Aug 2006
Last Updated on STN: 17 Aug 2006

L14 ANSWER 3 OF 85 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2006:788384 SCISEARCH

THE GENUINE ARTICLE: 072FI

TITLE: Prostasin attenuates inducible nitric oxide synthase expression in lipopolysaccharide-induced urinary bladder inflammation

AUTHOR: Chen L M; Wang C; Chen M Q; Marcello M R; Chao J; Chao L; Chai K X (Reprint)

CORPORATE SOURCE: Univ Cent Florida, Dept Mol Biol & Microbiol, 4000 Cent Florida Blvd, Orlando, FL 32816 USA (Reprint); Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32816 USA; Univ Cent Florida, Biomol Sci Ctr, Orlando, FL 32816 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA
kxchai@mail.ucf.edu

COUNTRY OF AUTHOR: USA

SOURCE: AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, (SEP 2006) Vol. 291, No. 3, pp. F567-F577.
ISSN: 0363-6127.

PUBLISHER: AMER PHYSIOLOGICAL SOC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA.

DOCUMENT TYPE: Article; Journal

LANGUAGE: English

REFERENCE COUNT: 52
ENTRY DATE: Entered STN: 31 Aug 2006
Last Updated on STN: 31 Aug 2006
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L14 ANSWER 4 OF 85 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 2006:565424 BIOSIS
DOCUMENT NUMBER: PREV200600568530
TITLE: A Spink1 gene mutation in a Thai patient with
fibrocalculous pancreatic diabetes.
AUTHOR(S): Snabboon, Thiti [Reprint Author]; Plengpanich, Wanee;
Sridama, Vitaya; Sunthornyothin, Sarat; Suwanwalaikorn,
Sompongse; Khovidhunkit, Weerapan
CORPORATE SOURCE: Chulalongkorn Univ, Fac Med, Dept Internal Med, Rama 4 Rd,
Bangkok 10330, Thailand
Thiti.S@chula.ac.th
SOURCE: Southeast Asian Journal of Tropical Medicine and Public
Health, (MAY 2006) Vol. 37, No. 3, pp. 559-562.
CODEN: SJTMAK. ISSN: 0125-1562.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 27 Oct 2006
Last Updated on STN: 27 Oct 2006

L14 ANSWER 5 OF 85 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 2006:556751 BIOSIS
DOCUMENT NUMBER: PREV200600558999
TITLE: Molecular markers in the early diagnosis of acute rejection
after renal transplant.
AUTHOR(S): Ortolani, M. [Reprint Author]; Cappuccilli, M. L.; Conte,
D.; La Manna, G.; D'Addio, F.; Borgnino, L. C.; Scolari, M.
P.; Stefoni, S.
CORPORATE SOURCE: St Orsola Hosp, Inst Nephrol Dialysis and Renal
Transplantat, Bologna, Italy
SOURCE: International Journal of Artificial Organs, (MAY 2006) Vol.
29, No. 5, pp. 524.
Meeting Info.: 32nd Congress of the European-Society-of-
Artificial-Organs. Umea, SWEDEN. June 21 -24, 2006.
European Soc Artificial Organs.
CODEN: IJAODS. ISSN: 0391-3988.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 27 Oct 2006
Last Updated on STN: 27 Oct 2006

L14 ANSWER 6 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:523415 HCAPLUS
DOCUMENT NUMBER: 145:186800
TITLE: Induction of release and up-regulated gene
expression of interleukin (IL)-8 in A549 cells
by serine proteinases
AUTHOR(S): Wang, Haiyan; Zheng, Yanshan; He, Shaoheng
CORPORATE SOURCE: Allergy and Inflammation Research Institute, the Key
Immunopharmacology Laboratory of Guangdong Province,
Shantou University Medical College, Shantou, 515031,
Peop. Rep. China
SOURCE: BMC Cell Biology (2006), 7, No pp. given
CODEN: BCBMAY; ISSN: 1471-2121
URL: <http://www.biomedcentral.com/content/pdf/1471-2121-7-22.pdf>
PUBLISHER: BioMed Central Ltd.
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English

REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 7 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:14535 HCAPLUS
DOCUMENT NUMBER: 142:111832
TITLE: Human serine proteinase
inhibitor, clade E, member 2 (SERPINE2) gene
expression as prognostic marker in colorectal
cancer
INVENTOR(S): Rowe, Michael W.; Moler, Edward J.; Randazzo, Filippo
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005001046	A2	20050106	WO 2004-US17408	20040603
WO 2005001046	A3	20060330		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2528077	AA	20050106	CA 2004-2528077	20040603
EP 1639079	A2	20060329	EP 2004-754096	20040603
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
PRIORITY APPLN. INFO.:			US 2003-475872P	P 20030603
			WO 2004-US17408	W 20040603

L14 ANSWER 8 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1125584 HCAPLUS
DOCUMENT NUMBER: 143:403958
TITLE: Serine proteinase inhibitor SPINT2 gene
expression as an indicator for angiogenesis
and its diagnostic and therapeutic uses
INVENTOR(S): Kearsey, Jonathan
PATENT ASSIGNEE(S): Exonhit Therapeutics SA, Fr.
SOURCE: Eur. Pat. Appl., 35 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1586587	A1	20051019	EP 2004-291020	20040416
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
PRIORITY APPLN. INFO.:			EP 2004-291020	20040416
REFERENCE COUNT:	9			THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 85 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 ACCESSION NUMBER: 2006:183286 BIOSIS
 DOCUMENT NUMBER: PREV200600185398
 TITLE: Constitutive expression of the granzyme B inhibitor PI-9 protects leukemic cells from granzyme B induced apoptosis.
 AUTHOR(S): Grullich, Carsten [Reprint Author]; Fritsch, Kristina; Finke, Jurgen
 CORPORATE SOURCE: Freiburg Univ, Med Ctr, Freiburg, Germany
 SOURCE: Blood, (NOV 16 2005) Vol. 106, No. 11, Part 1, pp. 848A-849A.
 Meeting Info.: 47th Annual Meeting of the American-Society-of-Hematology. Atlanta, GA, USA. December 10 -13, 2005. Amer Soc Hematol.
 CODEN: BLOOAW. ISSN: 0006-4971.
 DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 15 Mar 2006
 Last Updated on STN: 15 Mar 2006

L14 ANSWER 10 OF 85 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 ACCESSION NUMBER: 2005:279839 BIOSIS
 DOCUMENT NUMBER: PREV200510068894
 TITLE: Transcriptome analysis of different multidrug-resistant gastric carcinoma cells.
 AUTHOR(S): Heim, Steffen; Lage, Hermann [Reprint Author]
 CORPORATE SOURCE: Inst Pathol, Charite Campus Mitte, Schumannstr 20-21, D-10117 Berlin, Germany
 hermann.lage@charite.de
 SOURCE: In Vivo (Attiki), (MAY-JUN 2005) Vol. 19, No. 3, pp. 583-590.
 CODEN: IVIVE4. ISSN: 0258-851X.
 DOCUMENT TYPE: Article
 LANGUAGE: English
 OTHER SOURCE: GenBank-S73906; EMBL-S73906; DDJB-S73906;
 GenBank-NM_006561; EMBL-NM_006561; DDJB-NM_006561;
 GenBank-AL034374; EMBL-AL034374; DDJB-AL034374;
 GenBank-U11690; EMBL-U11690; DDJB-U11690; GenBank-Z49995;
 EMBL-Z49995; DDJB-Z49995; GenBank-Z79610; EMBL-Z79610;
 DDJB-Z79610; GenBank-NM_015935; EMBL-NM_015935;
 DDJB-NM_015935; GenBank-AF069762; EMBL-AF069762;
 DDJB-AF069762; GenBank-X00364; EMBL-X00364; DDJB-X00364;
 GenBank-U02328; EMBL-U02328; DDJB-U02328; GenBank-AF169692;
 EMBL-AF169692; DDJB-AF169692; GenBank-M22299; EMBL-M22299;
 DDJB-M22299; GenBank-AI017284; EMBL-AI017284;
 DDJB-AI017284; GenBank-U29953; EMBL-U29953; DDJB-U29953;
 GenBank-AF133270; EMBL-AF133270; DDJB-AF133270;
 GenBank-AF000974; EMBL-AF000974; DDJB-AF000974;
 GenBank-AB014458; EMBL-AB014458; DDJB-AB014458
 ENTRY DATE: Entered STN: 27 Jul 2005
 Last Updated on STN: 27 Jul 2005

L14 ANSWER 11 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:550784 HCAPLUS
 DOCUMENT NUMBER: 143:437749
 TITLE: Expression of hurpin, a serine proteinase inhibitor, in normal and pathological skin: Overexpression and redistribution in psoriasis and cutaneous carcinomas
 AUTHOR(S): Moussali, Hayat; Bylaite, Matilda; Welss, Thomas; Abts, Harry F.; Ruzicka, Thomas; Walz, Markus

CORPORATE SOURCE: Department of Dermatology, Heinrich-Heine University,
Duesseldorf, Germany
SOURCE: Experimental Dermatology (2005), 14(6), 420-428
CODEN: EXDEEY; ISSN: 0906-6705
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 12 OF 85 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 2004478021 MEDLINE
DOCUMENT NUMBER: PubMed ID: 15362859
TITLE: Identification and activity of a lower eukaryotic serine
proteinase inhibitor (serpin) from *Cyanea capillata*:
analysis of a jellyfish serpin, jellypin.
AUTHOR: Cole Elisabeth B; Miller David; Rometo David; Greenberg
Robert M; Bromme Dieter; Cataltepe Sule; Pak Stephen C;
Mills David R; Silverman Gary A; Luke Cliff J
CORPORATE SOURCE: Department of Pediatrics, Harvard Medical School and
Division of Newborn Medicine, Children's Hospital, 300
Longwood Avenue, Boston, Massachusetts 02115-5737, USA.
CONTRACT NUMBER: AR46182 (NIAMS)
CA86007 (NCI)
CA87006 (NCI)
SOURCE: Biochemistry, (2004 Sep 21) Vol. 43, No. 37, pp. 11750-9.
Journal code: 0370623. ISSN: 0006-2960.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200411
ENTRY DATE: Entered STN: 28 Sep 2004
Last Updated on STN: 2 Nov 2004
Entered Medline: 1 Nov 2004

L14 ANSWER 13 OF 85 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN
ACCESSION NUMBER: 2004:360866 BIOSIS
DOCUMENT NUMBER: PREV200400359675
TITLE: Discrimination of genotoxic from non-genotoxic carcinogens
by gene expression profiling.
AUTHOR(S): van Delft, J. H. M. [Reprint Author]; Van Agen, E.; van
Breda, S. G. J.; Herwijnen, M. H.; Staal, Y. C. M.;
Kleijnans, J. C. S.
CORPORATE SOURCE: Dept Hlth Risk Anal and Toxicol, Maastricht Univ, POB 616,
NL-6200 MD, Maastricht, Netherlands
j.vandelft@grat.unimaas.nl
SOURCE: Carcinogenesis (Oxford), (July 2004) Vol. 25, No. 7, pp.
1265-1276. print.
CODEN: CRNGDP. ISSN: 0143-3334.
DOCUMENT TYPE: Article
LANGUAGE: English
OTHER SOURCE: DDBJ-D13866; EMBL-D13866; GenBank-D13866; DDBJ-J04718;
EMBL-J04718; GenBank-J04718; DDBJ-K00065; EMBL-K00065;
GenBank-K00065; DDBJ-L22473; EMBL-L22473; GenBank-L22473;
DDBJ-M16650; EMBL-M16650; GenBank-M16650; DDBJ-M18082;
EMBL-M18082; GenBank-M18082; DDBJ-M21154; EMBL-M21154;
GenBank-M21154; DDBJ-M30773; EMBL-M30773; GenBank-M30773;
DDBJ-NM_000558; EMBL-NM_000558; GenBank-NM_000558;
DDBJ-NM_001022; EMBL-NM_001022; GenBank-NM_001022;
DDBJ-U03106; EMBL-U03106; GenBank-U03106; DDBJ-U32944;
EMBL-U32944; GenBank-U32944; DDBJ-U58143; EMBL-U58143;
GenBank-U58143; DDBJ-X02308; EMBL-X02308; GenBank-X02308;

DDBJ-X04224; EMBL-X04224; GenBank-X04224; DDBJ-X06661;
EMBL-X06661; GenBank-X06661; DDBJ-X12795; EMBL-X12795;
GenBank-X12795; DDBJ-X97260; EMBL-X97260; GenBank-X97260;
DDBJ-XM_004988; EMBL-XM_004988; GenBank-XM_004988;
DDBJ-XM_006344; EMBL-XM_006344; GenBank-XM_006344

ENTRY DATE: Entered STN: 5 Sep 2004
Last Updated on STN: 5 Sep 2004

L14 ANSWER 14 OF 85 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

ACCESSION NUMBER: 2005:111136 BIOSIS
DOCUMENT NUMBER: PREV200500113789
TITLE: Upregulation of the NNP-1 (novel nuclear protein-1,
D21S2056E) gene in keloid tissue determined by cDNA
microarray and in situ hybridization.
AUTHOR(S): Na, G.-Y. [Reprint Author]; Seo, S.-K.; Lee, S.-J.; Kim,
D.-W.; Kim, M.-K.; Kim, J.-C.
CORPORATE SOURCE: Sch MedDept Dermatol, Kyungpook Natl Univ, 50 Samdeok 2 Ga,
Chung Gu, Daegu, 700721, South Korea
nagy@knu.ac.kr
SOURCE: British Journal of Dermatology, (December 2004) Vol. 151,
No. 6, pp. 1143-1149. print.
CODEN: BJDEAZ. ISSN: 0007-0963.
DOCUMENT TYPE: Article
LANGUAGE: English
OTHER SOURCE: DDBJ-NM_001236; EMBL-NM_001236; GenBank-NM_001236;
DDBJ-NM_000088; EMBL-NM_000088; GenBank-NM_000088;
DDBJ-NM_001235; EMBL-NM_001235; GenBank-NM_001235;
DDBJ-NM_001686; EMBL-NM_001686; GenBank-NM_001686;
DDBJ-NM_003169; EMBL-NM_003169; GenBank-NM_003169;
DDBJ-NM_003683; EMBL-NM_003683; GenBank-NM_003683;
DDBJ-NM_004512; EMBL-NM_004512; GenBank-NM_004512;
DDBJ-NM_012319; EMBL-NM_012319; GenBank-NM_012319;
DDBJ-NM_032692; EMBL-NM_032692; GenBank-NM_032692
ENTRY DATE: Entered STN: 23 Mar 2005
Last Updated on STN: 23 Mar 2005

L14 ANSWER 15 OF 85 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on
STN

ACCESSION NUMBER: 2004:1054235 SCISEARCH
THE GENUINE ARTICLE: 865CO
TITLE: Localization and expression of TSP50 protein in
human and rodent testes
AUTHOR: Xu H P; Yuan L M; Shan J D; Feng H L (Reprint)
CORPORATE SOURCE: N Shore Univ Hosp, Ctr Human Reprod, Dept Obstet &
Gynecol, 300 Community Dr, Manhasset, NY 11030 USA
(Reprint); N Shore Univ Hosp, Ctr Human Reprod, Dept
Obstet & Gynecol, Manhasset, NY 11030 USA; SUNY Stony
Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794
USA; NYU, Sch Med, Dept Obstet & Gynecol, Manhasset, NY
USA
COUNTRY OF AUTHOR: USA
SOURCE: UROLOGY, (OCT 2004) Vol. 64, No. 4, pp. 826-832.
ISSN: 0090-4295.
PUBLISHER: ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, NY
10010-1710 USA.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 26
ENTRY DATE: Entered STN: 27 Dec 2004
Last Updated on STN: 27 Dec 2004
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L14 ANSWER 16 OF 85 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on

STN

ACCESSION NUMBER: 2005:32493 BIOSIS
DOCUMENT NUMBER: PREV200500032392
TITLE: Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling.
AUTHOR(S): Selvanayagam, Zachariah E.; Cheung, Tak Hong; Wei, Nien; Vittal, Ragini; Lo, Keith Wing Kit; Yeo, Winnie; Kita, Tsunekazu; Ravatn, Roald; Chung, Tony Kwok Hung; Wong, Yick Fu [Reprint Author]; Chin, Khew-Voon
CORPORATE SOURCE: Prince Wales HospDept Obstet and Gynecol, Chinese Univ Hong Kong, Hong Kong, Hong Kong, China
yickfuwong@cuhk.edu.hk; chinkv@rci.rutgers.edu
SOURCE: Cancer Genetics and Cytogenetics, (October 1 2004) Vol. 154, No. 1, pp. 63-66. print.
CODEN: CGCYDF. ISSN: 0165-4608.
DOCUMENT TYPE: Article
LANGUAGE: English
OTHER SOURCE: DDBJ-A1151105; EMBL-A1151105; GenBank-A1151105;
DDBJ-A1367095; EMBL-A1367095; GenBank-A1367095;
DDBJ-A1636025; EMBL-A1636025; GenBank-A1636025;
DDBJ-AA142971; EMBL-AA142971; GenBank-AA142971;
DDBJ-AA262080; EMBL-AA262080; GenBank-AA262080;
DDBJ-AA281784; EMBL-AA281784; GenBank-AA281784;
DDBJ-AA410517; EMBL-AA410517; GenBank-AA410517;
DDBJ-AA425419; EMBL-AA425419; GenBank-AA425419;
DDBJ-AA465353; EMBL-AA465353; GenBank-AA465353;
DDBJ-AA485226; EMBL-AA485226; GenBank-AA485226;
DDBJ-AA670200; EMBL-AA670200; GenBank-AA670200;
DDBJ-AA779480; EMBL-AA779480; GenBank-AA779480;
DDBJ-AA864479; EMBL-AA864479; GenBank-AA864479;
DDBJ-AI262370; EMBL-AI262370; GenBank-AI262370;
DDBJ-T56021; EMBL-T56021; GenBank-T56021; DDBJ-T90374;
EMBL-T90374; GenBank-T90374
ENTRY DATE: Entered STN: 12 Jan 2005
Last Updated on STN: 12 Jan 2005

L14 ANSWER 17 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:737887 HCAPLUS
DOCUMENT NUMBER: 139:241376
TITLE: Sequences of a human serine
proteinase sequence homolog and uses in
diagnosis, therapy and drug screening
INVENTOR(S): Smolyar, Alex
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076609	A1	20030918	WO 2003-EP2406	20030310
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

AU 2003218714 A1 20030922 AU 2003-218714 20030310
 PRIORITY APPLN. INFO.: US 2002-362998P P 20020311
 US 2002-399132P P 20020730
 WO 2003-EP2406 W 20030310
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 18 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:719596 HCAPLUS
 DOCUMENT NUMBER: 139:241362
 TITLE: Protein and cDNA and genomic sequences of a
 human serine proteinase
 sequence homolog, its tissue expression,
 SNPs, and therapeutic use
 INVENTOR(S): Yan, Chunhua; Li, Jiayin
 PATENT ASSIGNEE(S): Applera Corporation, USA
 SOURCE: PCT Int. Appl., 72 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074669	A2	20030912	WO 2003-US6285	20030303
WO 2003074669	A3	20040910		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2478391	AA	20030912	CA 2003-2478391	20030303
AU 2003225626	A1	20030916	AU 2003-225626	20030303
US 2003215848	A1	20031120	US 2003-376344	20030303
EP 1481079	A2	20041201	EP 2003-743730	20030303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:		US 2002-361047P		P 20020301
		WO 2003-US6285		W 20030303

L14 ANSWER 19 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:678994 HCAPLUS
 DOCUMENT NUMBER: 139:193622
 TITLE: A serine proteinase inhibitor peptide derived from the
 LEKTI proteinase inhibitor for inhibiting serine
 proteinases or viral propagation
 INVENTOR(S): Forssmann, Wolf-Georg; Kirchhoff, Frank; Muench, Jan;
 Kreutzmann, Peter; Maegert, Hans-Juergen
 PATENT ASSIGNEE(S): IPF Pharmaceuticals GmbH, Germany
 SOURCE: PCT Int. Appl., 24 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2003070953 A1 20030828 WO 2003-EP1704 20030220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003210317 A1 20030909 AU 2003-210317 20030220
EP 1476554 A1 20041117 EP 2003-742557 20030220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.: DE 2002-10207602 A 20020222
DE 2002-10208302 A 20020226
DE 2002-10209307 A 20020302
DE 2002-10220802 A 20020510
EP 2002-15418 A 20020711
WO 2003-EP1704 W 20030220
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 20 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:610633 HCAPLUS
DOCUMENT NUMBER: 139:160840
TITLE: Sequences of a human serine
proteinase sequence homolog and uses in
diagnosis, therapy and drug screening
INVENTOR(S): Xiao, Yonghong; Russel, Annette J.
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany; Bayer Healthcare AG
SOURCE: PCT Int. Appl., 151 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003064651	A2	20030807	WO 2003-EP812	20030128
WO 2003064651	A3	20040513		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003238359	A1	20030902	AU 2003-238359	20030128
PRIORITY APPLN. INFO.:			US 2002-351376P	P 20020128
			US 2002-405299P	P 20020823
			WO 2003-EP812	W 20030128

L14 ANSWER 21 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:58107 HCAPLUS
DOCUMENT NUMBER: 138:118517
TITLE: Protein, gene and cDNA sequences of a human
serine proteinase inhibitor sequence
homolog and their uses in drug screening

INVENTOR(S): Hu, Song; Zhong, Min; Ladunga, Istvan
 PATENT ASSIGNEE(S): Applera Corporation, USA
 SOURCE: PCT Int. Appl., 23 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006484	A2	20030123	WO 2002-US21670	20020710
WO 2003006484	A3	20031023		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005075283	A1	20050407	US 2001-903582	20010713
CA 2466670	AA	20030123	CA 2002-2466670	20020710
AU 2002326351	A1	20030129	AU 2002-326351	20020710
EP 1415155	A2	20040506	EP 2002-761055	20020710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:			US 2001-903582	A 20010713
			WO 2002-US21670	W 20020710

L14 ANSWER 22 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:6093 HCAPLUS

DOCUMENT NUMBER: 138:68924

TITLE: Protein and cDNA sequences of a human dendritic cell transmembrane serine protease (DCTSP) and uses in drug screening

INVENTOR(S): Anderson, Dirk M.; Virca, G. Duke

PATENT ASSIGNEE(S): Immunex Corporation, USA

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000850	A2	20030103	WO 2002-US19708	20020620
WO 2003000850	A3	20041229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003082783	A1	20030501	US 2002-177661	20020620
US 6794173	B2	20040921		
US 2005214785	A1	20050929	US 2004-910507	20040802

PRIORITY APPLN. INFO.:

US 2001-299606P

P 20010620

US 2002-177661

A3 20020620

L14 ANSWER 23 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:737282 HCAPLUS

DOCUMENT NUMBER: 139:256337

TITLE: Human serine protease sequence homologs and cDNAs encoding them and related antibodies for therapeutic and diagnostic use

INVENTOR(S): Shi, Yanggu; Ruben, Steven M.; Ni, Jian; Young, Paul E.

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 133 pp., Cont.-in-part of U.S. Ser. No. 125,459.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003175938	A1	20030918	US 2002-319519	20021216
WO 2000068247	A2	20001116	WO 2000-US12207	20000505
WO 2000068247	A3	20010628		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2002068320	A1	20020606	US 2001-804156	20010313
US 2002119925	A1	20020829	US 2001-946633	20010906
US 2002197701	A1	20021226	US 2002-67761	20020208
US 2002192800	A1	20021219	US 2002-125459	20020419
PRIORITY APPLN. INFO.:			US 1999-133239P	P 19990507
			US 1999-135163P	P 19990520
			US 1999-147005P	P 19990803
			US 1999-152935P	P 19990909
			US 1999-162979P	P 19991101
			US 2000-189025P	P 20000314
			WO 2000-US12207	A2 20000505
			US 2000-597839	B1 20000620
			US 2000-597842	B2 20000620
			US 2000-597843	B2 20000620
			US 2001-804156	B1 20010313
			US 2001-946633	B1 20010906
			US 2002-67761	A2 20020208
			US 2002-125459	A2 20020419
			WO 2000-US16848	A2 20000620

L14 ANSWER 24 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:717624 HCAPLUS

DOCUMENT NUMBER: 139:241351

TITLE: Human transmembrane serine protease TADG-12 overexpressed in ovarian carcinoma and diagnosis and treatment of cancer

INVENTOR(S): O'Brien, Timothy J.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 67 pp., Cont.-in-part of U. S. Ser. No. 650,371.

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003170707	A1	20030911	US 2003-357175	20030203
US 6294663	B1	20010925	US 2000-518046	20000302
US 6942978	B1	20050913	US 2000-650371	20000828
PRIORITY APPLN. INFO.:			US 2000-518046	A3 20000302
			US 2000-650371	A2 20000828
			US 1999-261416	A2 19990303

L14 ANSWER 25 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:492563 HCAPLUS
DOCUMENT NUMBER: 139:49114
TITLE: Sequence homologs of transmembrane serine proteases, cDNAs encoding them, and their possible diagnostic and therapeutic uses
INVENTOR(S): Madison, Edwin L.; Ong, Edgar O.; Yeh, Jiunn-Chern
PATENT ASSIGNEE(S): Corvas International, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 137 pp., Cont.-in-part of U.S. Ser. No. 657,986.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003119168	A1	20030626	US 2001-776191	20010202
US 6797504	B1	20040928	US 2000-657986	20000908
ZA 2002005678	A	20031016	ZA 2002-5678	20020716
PRIORITY APPLN. INFO.:			US 2000-179982P	P 20000203
			US 2000-183542P	P 20000218
			US 2000-213124P	P 20000622
			US 2000-220970P	P 20000726
			US 2000-657986	A2 20000908
			US 2000-234840P	P 20000922

L14 ANSWER 26 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:199568 HCAPLUS
DOCUMENT NUMBER: 138:364649
TITLE: Inhibition of Serine Proteinases Plasmin, Trypsin, Subtilisin A, Cathepsin G, and Elastase by LEKTI: A Kinetic Analysis
AUTHOR(S): Mitsudo, Kenji; Jayakumar, Arumugam; Henderson, Ying; Frederick, Mitchell J.; Kang, Ya'an; Wang, Mary; El-Naggar, Adel K.; Clayman, Gary L.
CORPORATE SOURCE: Departments of Head and Neck Surgery, Pathology, and Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030-4095, USA
SOURCE: Biochemistry (2003), 42(13), 3874-3881
CODEN: BICHAW; ISSN: 0006-2960
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 27 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:614307 HCAPLUS
 DOCUMENT NUMBER: 139:229169
 TITLE: Serine proteinase inhibitor-9, an endogenous blocker of granzyme B/perforin lytic pathway, is hyperexpressed during acute rejection of renal allografts
 AUTHOR(S): Muthukumar, Thangamani; Ding, Ruchuang; Dadhania, Darshana; Medeiros, Mara; Li, Baogui; Sharma, Vijay K.; Hartono, Choli; Serur, David; Seshan, Surya V.; Volk, Hans-Dieter; Reinke, Petra; Kapur, Sandip; Suthanthiran, Manikkam
 CORPORATE SOURCE: Departments of Medicine and Transplantation Medicine, Division of Nephrology, Weill Medical College of Cornell University, New York, NY, USA
 SOURCE: Transplantation (2003), 75(9), 1565-1570
 CODEN: TRPLAU; ISSN: 0041-1337
 PUBLISHER: Lippincott Williams & Wilkins
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 28 OF 85 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2003:763337 SCISEARCH
 THE GENUINE ARTICLE: 717EV
 TITLE: Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages
 AUTHOR: Komatsu N (Reprint); Takata M; Otsuki N; Toyama T; Ohka R; Takehara K; Saijoh K
 CORPORATE SOURCE: Kanazawa Univ, Sch Med, Grad Sch Med Sci, Dept Dermatol, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan (Reprint); Kanazawa Univ, Sch Med, Grad Sch Med Sci, Dept Dermatol, Kanazawa, Ishikawa 9208641, Japan; Kanazawa Univ, Sch Med, Grad Sch Med Sci, Dept Hyg, Kanazawa, Ishikawa 9208641, Japan; Maizuru Kyosai Hosp, Dept Dermatol, Kyoto, Japan
 COUNTRY OF AUTHOR: Japan
 SOURCE: JOURNAL OF INVESTIGATIVE DERMATOLOGY, (SEP 2003) Vol. 121, No. 3, pp. 542-549.
 ISSN: 0022-202X.
 PUBLISHER: BLACKWELL PUBLISHING INC, 350 MAIN ST, MALDEN, MA 02148 USA.
 DOCUMENT TYPE: Article; Journal
 LANGUAGE: English
 REFERENCE COUNT: 41
 ENTRY DATE: Entered STN: 19 Sep 2003
 Last Updated on STN: 19 Sep 2003
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L14 ANSWER 29 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:273230 HCAPLUS
 DOCUMENT NUMBER: 139:113601
 TITLE: Homologous proteins with different folds: the three-dimensional structures of domains 1 and 6 of the multiple Kazal-type inhibitor LEKTI
 AUTHOR(S): Lauber, Thomas; Schulz, Axel; Schweimer, Kristian; Adermann, Knut; Marx, Ute C.
 CORPORATE SOURCE: Lehrstuhl fur Biopolymere, Universitat Bayreuth, Bayreuth, D-95440, Germany
 SOURCE: Journal of Molecular Biology (2003), 328(1), 205-219
 CODEN: JMOBAK; ISSN: 0022-2836
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal

LANGUAGE: English
REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 30 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:658158 HCAPLUS
DOCUMENT NUMBER: 137:197338
TITLE: Method for purifying human serine
proteinase inhibitors HF7072, HF7638 and
HF14448 and their use in disease diagnosis and
treatment
INVENTOR(S): Walden, Michael; Maegert, Hans-Juergen; Kreutzmann,
Peter; John, Harald; Staendker, Ludger; Forssmann,
Wolf-Georg
PATENT ASSIGNEE(S): IPF Pharmaceuticals GmbH, Germany
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066513	A2	20020829	WO 2002-EP1720	20020219
WO 2002066513	A3	20030403		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: DE 2001-10107997 A 20010219

L14 ANSWER 31 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:256448 HCAPLUS
DOCUMENT NUMBER: 136:291003
TITLE: Sequences of a human serine
proteinase sequence homolog and uses in
diagnosis, therapy and drug screening
INVENTOR(S): Smolyar, Alex
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002026957	A2	20020404	WO 2001-EP11125	20010926
WO 2002026957	A3	20021212		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,			

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2001093846 A5 20020408 AU 2001-93846 20010926
 PRIORITY APPLN. INFO.: US 2000-235921P P 20000928
 WO 2001-EP11125 W 20010926

L14 ANSWER 32 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:658737 HCAPLUS
 DOCUMENT NUMBER: 137:197519
 TITLE: Cloning of cDNAs for human serine proteases
 and therapeutic use thereof
 INVENTOR(S): Ni, Jian; Shi, Yanggu; Ruben, Steven M.
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 87 pp., Cont.-in-part of Appl.
 No. PCT/US00/12207.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002119925	A1	20020829	US 2001-946633	20010906
WO 2000068247	A2	20001116	WO 2000-US12207	20000505
WO 2000068247	A3	20010628		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002192800	A1	20021219	US 2002-125459	20020419
US 2003175938	A1	20030918	US 2002-319519	20021216
PRIORITY APPLN. INFO.:				
			US 1999-133239P	P 19990507
			US 1999-147005P	P 19990803
			US 1999-152935P	P 19990909
			US 1999-162979P	P 19991101
			WO 2000-US12207	A2 20000505
			US 1999-135163P	P 19990520
			US 2000-189025P	P 20000314
			US 2000-597839	B1 20000620
			US 2000-597842	B2 20000620
			US 2000-597843	B2 20000620
			WO 2000-US16848	A2 20000620
			US 2001-804156	B1 20010313
			US 2001-946633	A1 20010906
			US 2002-67761	A2 20020208
			US 2002-125459	A2 20020419

L14 ANSWER 33 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:811113 HCAPLUS
 DOCUMENT NUMBER: 140:158594
 TITLE: Human 10.12-kDa serine proteinase sequence homolog and
 its cDNA and therapeutic use
 INVENTOR(S): Mao, Yumin; Xie, Yi
 PATENT ASSIGNEE(S): Bode Gene Development Co., Ltd., Shanghai, Peop. Rep.
 China
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 29 pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent

LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1380412	A	20021120	CN 2001-105921	20010410
PRIORITY APPLN. INFO.:			CN 2001-105921	20010410

L14 ANSWER 34 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:307488 HCAPLUS
DOCUMENT NUMBER: 138:282411
TITLE: Protein and cDNA sequences of a 9.02-kilodalton human serine proteinase-like protein and their therapeutic uses
INVENTOR(S): Mao, Yumin; Xie, Yi
PATENT ASSIGNEE(S): Shanghai Bode Gene Development Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 31 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1352297	A	20020605	CN 2000-127275	20001106
PRIORITY APPLN. INFO.:			CN 2000-127275	20001106

L14 ANSWER 35 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:307487 HCAPLUS
DOCUMENT NUMBER: 138:282410
TITLE: Protein and cDNA sequences of a 10.78-kilodalton human serine proteinase-like protein and their therapeutic uses
INVENTOR(S): Mao, Yumin; Xie, Yi
PATENT ASSIGNEE(S): Shanghai Bode Gene Development Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 32 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1352296	A	20020605	CN 2000-127218	20001106
PRIORITY APPLN. INFO.:			CN 2000-127218	20001106

L14 ANSWER 36 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:307485 HCAPLUS
DOCUMENT NUMBER: 138:282408
TITLE: Protein and cDNA sequences of a 11-kilodalton human serine proteinase-like protein and their therapeutic uses
INVENTOR(S): Mao, Yumin; Xie, Yi
PATENT ASSIGNEE(S): Shanghai Bode Gene Development Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 32 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
CN 1352294	A	20020605	CN 2000-127131	20001102
PRIORITY APPLN. INFO.:			CN 2000-127131	20001102

L14 ANSWER 37 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:810760 HCAPLUS
DOCUMENT NUMBER: 137:289979
TITLE: Protein and cDNA sequences of a novel human nervous serine proteinase inhibitor 83.27 and therapeutic use thereof
INVENTOR(S): Mao, Yumin; Xie, Yi; Wu, Hai
PATENT ASSIGNEE(S): Shanghai Bode Gene Development Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 37 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
CN 1333249	A	20020130	CN 2000-117032	20000707
PRIORITY APPLN. INFO.:			CN 2000-117032	20000707

L14 ANSWER 38 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:275265 HCAPLUS
DOCUMENT NUMBER: 137:61737
TITLE: Serine proteinase inhibitor 9 can be recognized by cytotoxic T lymphocytes of epithelial cancer patients
AUTHOR(S): Tanaka, Koji; Harashima, Nanae; Niiya, Fumihiko; Miyagi, Yoshiaki; Hida, Naoya; Ochi, Mika; Imai, Nobue; Harada, Mamoru; Itoh, Kyogo; Shichijo, Shigeki
CORPORATE SOURCE: Department of Immunology, Kurume University School of Medicine, Fukuoka, 830-0011, Japan
SOURCE: Japanese Journal of Cancer Research (2002), 93(2), 198-208
CODEN: JJCREP; ISSN: 0910-5050
PUBLISHER: Japanese Cancer Association
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 39 OF 85 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 2002159727 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11891144
TITLE: The 15-domain serine proteinase inhibitor LEKTI: biochemical properties, genomic organization, and pathophysiological role.
AUTHOR: Magert Hans-Jurgen; Kreutzmann P; Drogemuller K; Standker L; Adermann K; Walden M; John H; Kortling H C; Forssmann W G
CORPORATE SOURCE: IPF PharmaCeuticals GmbH, An-Institut der Medizinischen Hochschule Hannover, Feodor-Lynen-Str. 31, D-30625 Hannover, Germany.. HJ-Maegert@gmx.de
SOURCE: European journal of medical research, (2002 Feb 21) Vol. 7, No. 2, pp. 49-56. Ref: 59
Journal code: 9517857. ISSN: 0949-2321.
PUB. COUNTRY: Germany: Germany, Federal Republic of
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200205
ENTRY DATE: Entered STN: 14 Mar 2002
Last Updated on STN: 2 Jan 2003
Entered Medline: 24 May 2002

L14 ANSWER 40 OF 85 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2002:518565 BIOSIS
DOCUMENT NUMBER: PREV200200518565
TITLE: Identification of genes with significantly differential expression levels in adenomatous vs. normal and cancerous colonic tissues.
AUTHOR(S): Liu, Thomas C. [Reprint author]; Selaru, Florin M. [Reprint author]; Zou, Tong-Tong [Reprint author]; Ying, Jing [Reprint author]; Xu, Yan [Reprint author]; Mori, Yuriko [Reprint author]; Sato, Fumiako [Reprint author]; Wang, Suna [Reprint author]; Olaru, Andreea [Reprint author]; Kimos, Martha [Reprint author]; Perry, Kellie [Reprint author]; Shibata, David [Reprint author]; Abraham, John M. [Reprint author]; Greenwald, Bruce D. [Reprint author]; Meltzer, Stephen J. [Reprint author]
CORPORATE SOURCE: Baltimore, MD, USA
SOURCE: Gastroenterology, (April, 2002) Vol. 122, No. 4 Suppl. 1, pp. A-122. print.
Meeting Info.: Digestive Disease Week and the 103rd Annual Meeting of the American Gastroenterological Association. San Francisco, CA, USA. May 19-22, 2002.
CODEN: GASTAB. ISSN: 0016-5085.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 9 Oct 2002
Last Updated on STN: 9 Oct 2002

L14 ANSWER 41 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:703797 HCAPLUS
DOCUMENT NUMBER: 135:269289
TITLE: Human transmembrane serine protease TADG-12 overexpressed in ovarian carcinoma and diagnosis treatment and prophylaxis of ovarian cancer
INVENTOR(S): O'Brien, Timothy J.; Underwood, Lowell J.
PATENT ASSIGNEE(S): The Board of Trustees of the University of Arkansas, USA
SOURCE: U.S., 63 pp., Cont.-in-part of U.S. Ser. No. 261,416.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6294663	B1	20010925	US 2000-518046	20000302
US 6291663	B1	20010918	US 1999-261416	19990303
US 6942978	B1	20050913	US 2000-650371	20000828
US 2003170707	A1	20030911	US 2003-357175	20030203
US 2003207316	A1	20031106	US 2003-455720	20030605
US 7067630	B2	20060627		
US 2006177866	A1	20060810	US 2006-400825	20060407
PRIORITY APPLN. INFO.:			US 1999-261416	A2 19990303
			US 2000-518046	A3 20000302

US 2000-650371 A2 20000828
US 2003-455720 A3 20030605

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 42 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:703054 HCAPLUS
DOCUMENT NUMBER: 135:267267
TITLE: Protein and cDNA sequences of a novel human protein
BTL.009 having proteinase inhibitor activity
INVENTOR(S): Delaria, Kathy; Roczniak, Steve; Davies, Christopher
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: U.S., 16 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6294648	B1	20010925	US 1999-358569	19990720
PRIORITY APPLN. INFO.:			US 1999-358569	19990720
REFERENCE COUNT:	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L14 ANSWER 43 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:75295 HCAPLUS
DOCUMENT NUMBER: 134:141769
TITLE: Protein having proteinase inhibitor activity
INVENTOR(S): Davies, Christopher; Chen, Dadong; Roczniak, Steve
PATENT ASSIGNEE(S): USA
SOURCE: U.S., 17 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6180607	B1	20010130	US 1999-369494	19990805
US 6689582	B1	20040210	US 2000-569670	20000512
PRIORITY APPLN. INFO.:			US 1999-369494	A3 19990805
REFERENCE COUNT:	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L14 ANSWER 44 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:669759 HCAPLUS
DOCUMENT NUMBER: 137:180817
TITLE: Protein and cDNA sequences of a novel human
serine proteinase 11 and therapeutic
use thereof
INVENTOR(S): Mao, Yumin; Xie, Yi
PATENT ASSIGNEE(S): Bode Gene Development Co., Ltd., Shanghai, Peop. Rep.
China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 32 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	-----	-----	-----	-----
CN 1325997	A	20011212	CN 2000-116286	20000531
PRIORITY APPLN. INFO.:			CN 2000-116286	20000531

L14 ANSWER 45 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:669758 HCAPLUS
 DOCUMENT NUMBER: 137:180816
 TITLE: Protein and cDNA sequences of a novel human serine proteinase 10 and therapeutic use thereof
 INVENTOR(S): Mao, Yumin; Xie, Yi
 PATENT ASSIGNEE(S): Bode Gene Development Co., Ltd., Shanghai, Peop. Rep. China
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 32 pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
CN 1325996	A	20011212	CN 2000-116278	20000531
PRIORITY APPLN. INFO.:			CN 2000-116278	20000531

L14 ANSWER 46 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:669757 HCAPLUS
 DOCUMENT NUMBER: 137:180815
 TITLE: Protein and cDNA sequences of a novel human signal peptidase 28 and therapeutic use thereof
 INVENTOR(S): Mao, Yumin; Xie, Yi
 PATENT ASSIGNEE(S): Bode Gene Development Co., Ltd., Shanghai, Peop. Rep. China
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 33 pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
CN 1325995	A	20011212	CN 2000-116274	20000531
PRIORITY APPLN. INFO.:			CN 2000-116274	20000531

L14 ANSWER 47 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:669756 HCAPLUS
 DOCUMENT NUMBER: 137:180814
 TITLE: Protein and cDNA sequences of a novel human serine proteinase 12 and therapeutic use thereof
 INVENTOR(S): Mao, Yumin; Xie, Yi
 PATENT ASSIGNEE(S): Bode Gene Development Co., Ltd., Shanghai, Peop. Rep. China
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 32 pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
CN 1325994	A	20011212	CN 2000-116268	20000531

PRIORITY APPLN. INFO.:

CN 2000-116268

20000531

L14 ANSWER 48 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:432118 HCAPLUS

DOCUMENT NUMBER: 136:397009

TITLE: Protein and cDNA sequences of a novel human
serine proteinase 9 and therapeutic
use thereof

INVENTOR(S): Mao, Yumin; Xie, Yi

PATENT ASSIGNEE(S): Bode Gene Development Co., Ltd., Shanghai, Peop. Rep.
ChinaSOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 31 pp.
CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1315555	A	20011003	CN 2000-115094	20000324
WO 2001079430	A2	20011025	WO 2001-CN396	20010323
WO 2001079430	A3	20020221		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001058150	A5	20011030	AU 2001-58150	20010323
PRIORITY APPLN. INFO.:			CN 2000-115094	A 20000324
			WO 2001-CN396	W 20010323

L14 ANSWER 49 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:43376 HCAPLUS

DOCUMENT NUMBER: 137:2308

TITLE: SERPINB12 is a novel member of the human ov-serpin
family that is widely expressed and inhibits
trypsin-like serine proteinasesAUTHOR(S): Askew, Yuko S.; Pak, Stephen C.; Luke, Cliff J.;
Askew, David J.; Cataltepe, Sule; Mills, David R.;
Kato, Hiroshi; Lehoczkzy, Jessica; Dewar, Ken; Birren,
Bruce; Silverman, Gary A.CORPORATE SOURCE: Department of Pediatrics, Harvard Medical School,
Children's Hospital, Boston, MA, 02115, USASOURCE: Journal of Biological Chemistry (2001), 276(52),
49320-49330

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular
Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 50 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:887928 HCAPLUS

DOCUMENT NUMBER: 136:367374

TITLE: Serine proteinase activation in esophageal cancer

AUTHOR(S): Tang, Wen-Hao; Friess, Helmut; Kekis, Panagiotis B.;
Martignoni, Marc E.; Fukuda, Akira; Roggo, Antoine;

CORPORATE SOURCE: Zimmermann, Arthur; Buchler, Markus W.
Department of Visceral and Transplantation Surgery,
University of Bern, Inselspital, Bern, CH-3010, Switz.
SOURCE: Anticancer Research (2001), 21(4A), 2249-2258
CODEN: ANTRD4; ISSN: 0250-7005
PUBLISHER: International Institute of Anticancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 51 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:759984 HCAPLUS
DOCUMENT NUMBER: 136:367296
TITLE: Expression of serine proteinase inhibitor
PP5/TFPI-2/MSPI decreases the invasive potential of
human choriocarcinoma cells in vitro and in vivo
AUTHOR(S): Jin, Ming-shou; Udagawa, Kaori; Miyagi, Etsuko;
Nakazawa, Tsuneo; Hirahara, Fumiki; Yasumitsu,
Hidetaro; Miyazaki, Kaoru; Nagashima, Yoji; Aoki,
Ichiro; Miyagi, Yohei
CORPORATE SOURCE: Department of Obstetrics and Gynecology, Yokohama City
University School of Medicine, Yokohama, 241-0815,
Japan
SOURCE: Gynecologic Oncology (2001), 83(2), 325-333
CODEN: GYNOA3; ISSN: 0090-8258
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 52 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:756383 HCAPLUS
DOCUMENT NUMBER: 136:52650
TITLE: Gene polymorphism in Netherton and common atopic
disease
AUTHOR(S): Walley, Andrew J.; Chavanas, Stephane; Moffatt, Miriam
F.; Esnouf, Robert M.; Ubhi, Baljinder; Lawrence,
Robert; Wong, Kenny; Abecasis, Goncalo R.; Jones, E.
Yvonne; Harper, John I.; Hovnanian, Alain; Cookson,
William O. C. M.
CORPORATE SOURCE: Wellcome Trust Centre for Human Genetics, University
of Oxford, Oxford, OX3 7BN, UK
SOURCE: Nature Genetics (2001), 29(2), 175-178
CODEN: NGENEC; ISSN: 1061-4036
PUBLISHER: Nature America Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 53 OF 85 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on
STN
ACCESSION NUMBER: 2002:316177 SCISEARCH
THE GENUINE ARTICLE: 538WZ
TITLE: Snake venom proteinases as tools in hemostasis studies:
Structure-function relationship of a plasminogen activator
purified from Trimeresurus stejnegeri venom
AUTHOR: Wisner A; Braud S; Bon C (Reprint)
CORPORATE SOURCE: Inst Pasteur, Venoms Unit, 25-28 Rue Docteur Roux, F-75724
Paris 15, France (Reprint); Inst Pasteur, Venoms Unit,
F-75724 Paris 15, France
COUNTRY OF AUTHOR: France

SOURCE: HAEMOSTASIS, (MAY-DEC 2001) Vol. 31, No. 3-6, pp. 133-140.
ISSN: 0301-0147.
PUBLISHER: KARGER, ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 46
ENTRY DATE: Entered STN: 26 Apr 2002
Last Updated on STN: 26 Apr 2002
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L14 ANSWER 54 OF 85 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2001:59288 SCISEARCH
THE GENUINE ARTICLE: 389TU
TITLE: Blood-borne RT-PCR assay for prostatic-specific transcripts to identify circulating prostate cells in cancer patients
AUTHOR: Laribi A; Berteau P; Gala J L; Eschwege P; Benoit G; Tombal B; Schmitt F; Loric S (Reprint)
CORPORATE SOURCE: Hop St Anne, Biochim Lab A, 184 Rue Faubourg St Antoine, F-75012 Paris, France (Reprint); St Antoine AP HP Univ Hosp, Biochem Lab A, Paris, France; St Antoine AP HP Univ Hosp, INSERM, U538, Paris, France; Inst Pasteur, Cellular Differentiat Lab, CNRS, URA 1960, Paris, France; Bicetre AP HP Univ Hosp, Dept Urol, Le Kremlin Bicetre, France; Bicetre AP HP Univ Hosp, Expt Surg Lab, Le Kremlin Bicetre, France; St Luc Univ Hosp, Appl Mol Technol Lab, Brussels, Belgium; St Luc Univ Hosp, Dept Urol, Brussels, Belgium; Queen Astrid Mil Hosp, Brussels, Belgium
COUNTRY OF AUTHOR: France; Belgium
SOURCE: EUROPEAN UROLOGY, (JAN 2001) Vol. 39, No. 1, pp. 65-71.
ISSN: 0302-2838.
PUBLISHER: KARGER, ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 40
ENTRY DATE: Entered STN: 26 Jan 2001
Last Updated on STN: 26 Jan 2001
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L14 ANSWER 55 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:628170 HCAPLUS
DOCUMENT NUMBER: 133:219455
TITLE: Human transmembrane serine protease TADG-12 overexpressed in ovarian carcinoma and diagnosis and treatment of cancer
INVENTOR(S): O'Brien, Timothy J.; Underwood, Lowell J.
PATENT ASSIGNEE(S): The Board of Trustees of the University of Arkansas, USA
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000052044	A1	20000908	WO 2000-US5612	20000302
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6291663	B1	20010918	US 1999-261416	19990303
CA 2362830	AA	20000908	CA 2000-2362830	20000302

SOURCE: Research, Brisbane, Australia.
 Cancer research, (1999 Jul 1) Vol. 59, No. 13, pp.
 3199-205.
 Journal code: 2984705R. ISSN: 0008-5472.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199907
 ENTRY DATE: Entered STN: 6 Aug 1999
 Last Updated on STN: 3 Mar 2000
 Entered Medline: 28 Jul 1999

L14 ANSWER 59 OF 85 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
 STN DUPLICATE 5

ACCESSION NUMBER: 1999:405519 BIOSIS
 DOCUMENT NUMBER: PREV199900405519
 TITLE: Testisin, a new human serine
 proteinase expressed by premeiotic
 testicular germ cells.
 AUTHOR(S): Scarman, A. L. [Reprint author]; Hooper, J. D. [Reprint
 author]; Normyle, J. F. [Reprint author]; Nicol, D.;
 Antalis, T. M. [Reprint author]
 CORPORATE SOURCE: Cellular Oncology Laboratory, Queensland Institute of
 Medical Research, Brisbane, QLD, Australia
 SOURCE: Biology of Reproduction, (1999) Vol. 60, No. SUPPL. 1, pp.
 257. print.
 Meeting Info.: Thirty-Second Annual Meeting of the Society
 for the Study of Reproduction. Pullman, Washington, USA.
 July 31-August 3, 1999. Society for the Study of
 Reproduction.
 CODEN: BIREBV. ISSN: 0006-3363.
 DOCUMENT TYPE: Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LANGUAGE: English
 ENTRY DATE: Entered STN: 8 Oct 1999
 Last Updated on STN: 8 Oct 1999

L14 ANSWER 60 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:568908 HCAPLUS
 DOCUMENT NUMBER: 129:198890
 TITLE: Cloning of human serine
 proteinases and a kinase involved in
 spermatogenesis and the suppression of testicular
 cancer
 INVENTOR(S): Antalis, Toni Marie; Hooper, John David
 PATENT ASSIGNEE(S): Amrad Operations Pty. Ltd., Australia
 SOURCE: PCT Int. Appl., 168 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9836054	A1	19980820	WO 1998-AU85	19980213
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,			

GA, GN, ML, MR, NE, SN, TD, TG

AU 9859734	A1	19980908	AU 1998-59734	19980213
US 6479274	B1	20021112	US 1998-23942	19980213
AU 774591	B2	20040701	AU 2000-72539	20001228
US 2003092154	A1	20030515	US 2002-40647	20020107

PRIORITY APPLN. INFO.: AU 1997-5101 A 19970213
AU 1997-422 A 19971118
AU 1998-59734 A3 19980213
US 1998-23942 A3 19980213
WO 1998-AU85 W 19980213

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 61 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:32025 HCAPLUS

DOCUMENT NUMBER: 130:77969

TITLE: A human serine protease HGBAB90 and a cDNA encoding it

INVENTOR(S): Southan, Christopher Donald; Clinkenbeard, Helen
Elizabeth; Burgess, Nicola Anne

PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK

SOURCE: Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 887414	A2	19981230	EP 1998-303064	19980421
EP 887414	A3	20021127		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6100059	A	20000808	US 1998-70526	19980430
CA 2231015	AA	19981209	CA 1998-2231015	19980505
JP 11075868	A2	19990323	JP 1998-157425	19980605
PRIORITY APPLN. INFO.:			GB 1997-11952	A 19970609
			EP 1997-309646	A 19971201

L14 ANSWER 62 OF 85 MEDLINE on STN DUPLICATE 6

ACCESSION NUMBER: 96283438 MEDLINE

DOCUMENT NUMBER: PubMed ID: 8648266

TITLE: Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease.

AUTHOR: Chao J; Schmaier A; Chen L M; Yang Z; Chao L

CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston 29425, USA.

CONTRACT NUMBER: DE 09731 (NIDCR)
HL 29397 (NHLBI)
HL 44083 (NHLBI)
+

SOURCE: The Journal of laboratory and clinical medicine, (1996 Jun) Vol. 127, No. 6, pp. 612-20.
Journal code: 0375375. ISSN: 0022-2143.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals

ENTRY MONTH: 199607

ENTRY DATE: Entered STN: 5 Aug 1996
Last Updated on STN: 3 Mar 2000
Entered Medline: 25 Jul 1996

L14 ANSWER 63 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:438821 HCAPLUS
DOCUMENT NUMBER: 125:137356
TITLE: Interaction of the human serine protease inhibitor
 α -1-antitrypsin with *Cryptosporidium parvum*
AUTHOR(S): Forney, John R.; Yang, Shiguang; Healey, Mark C.
CORPORATE SOURCE: College Science, Utah State University, Logan, UT,
84322-5500, USA
SOURCE: Journal of Parasitology (1996), 82(3), 496-502
CODEN: JOPAA2; ISSN: 0022-3395
PUBLISHER: American Society of Parasitologists
DOCUMENT TYPE: Journal
LANGUAGE: English

L14 ANSWER 64 OF 85 MEDLINE on STN DUPLICATE 7
ACCESSION NUMBER: 96435910 MEDLINE
DOCUMENT NUMBER: PubMed ID: 8838796
TITLE: Structure and chromosomal localization of the human
prostasin (PRSS8) gene.
AUTHOR: Yu J X; Chao L; Ward D C; Chao J
CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, Medical
University of South Carolina, Charleston 29425, USA.
CONTRACT NUMBER: DE 09731 (NIDCR)
HL 29397 (NHLBI)
SOURCE: Genomics, (1996 Mar 15) Vol. 32, No. 3, pp. 334-40.
Journal code: 8800135. ISSN: 0888-7543.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: GENBANK-U33446
ENTRY MONTH: 199702
ENTRY DATE: Entered STN: 19 Feb 1997
Last Updated on STN: 3 Mar 2000
Entered Medline: 6 Feb 1997

L14 ANSWER 65 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:103309 HCAPLUS
DOCUMENT NUMBER: 124:252060
TITLE: Proastasin: a novel human serine
proteinase. purification, characterization and
cloning of its cDNA and gene
AUTHOR(S): Yu, Xuezheng
CORPORATE SOURCE: Medical Univ. of South Carolina, Charleston, SC, USA
SOURCE: (1995) 120 pp. Avail.: Univ. Microfilms Int., Order
No. DA9600553
From: Diss. Abstr. Int., B 1995, 56(9), 4744
DOCUMENT TYPE: Dissertation
LANGUAGE: English

L14 ANSWER 66 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:1001753 HCAPLUS
DOCUMENT NUMBER: 124:78204
TITLE: Molecular cloning, expression, and
partial characterization of two novel members of the
ovalbumin family of serine proteinase inhibitors
AUTHOR(S): Sprecher, Cindy A.; Morgenstern, Kurt A.; Mathewes,
Shannon; Dahlen, Jeffrey R.; Schrader, Sara K.;
Foster, Donald C.; Kisiel, Walter
CORPORATE SOURCE: ZymoGenetics, Inc., Seattle, WA, 98102, USA
SOURCE: Journal of Biological Chemistry (1995), 270(50),
29854-61
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Bio

DOCUMENT TYPE: logy
Journal
LANGUAGE: English

L14 ANSWER 67 OF 85 MEDLINE on STN DUPLICATE 8
ACCESSION NUMBER: 95286644 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7768952
TITLE: Molecular cloning, tissue-specific
expression, and cellular localization of human
prostasin mRNA.
AUTHOR: Yu J X; Chao L; Chao J
CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, Medical
University of South Carolina, Charleston 29425, USA.
CONTRACT NUMBER: DE 09731 (NIDCR)
HL 29397 (NHLBI)
SOURCE: The Journal of biological chemistry, (1995 Jun 2) Vol. 270,
No. 22, pp. 13483-9.
Journal code: 2985121R. ISSN: 0021-9258.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: GENBANK-L41351; GENBANK-U33446
ENTRY MONTH: 199507
ENTRY DATE: Entered STN: 13 Jul 1995
Last Updated on STN: 3 Mar 2000
Entered Medline: 5 Jul 1995

L14 ANSWER 68 OF 85 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on
STN
ACCESSION NUMBER: 1996:4749 SCISEARCH
THE GENUINE ARTICLE: TH910
TITLE: Molecular cloning of bomapin, a novel
human serine proteinase
inhibitor that is expressed specifically in the
bone marrow.
AUTHOR: Riewald M (Reprint); Schleef R R
CORPORATE SOURCE: Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA USA
COUNTRY OF AUTHOR: USA
SOURCE: BLOOD, (15 NOV 1995) Vol. 86, No. 10, Supp. [1], pp.
1971-1971.
ISSN: 0006-4971.
PUBLISHER: W B SAUNDERS CO, INDEPENDENCE SQUARE WEST CURTIS CENTER,
STE 300, PHILADELPHIA, PA 19106-3399.
DOCUMENT TYPE: Conference; Journal
FILE SEGMENT: LIFE; CLIN
LANGUAGE: English
REFERENCE COUNT: 0
ENTRY DATE: Entered STN: 1996
Last Updated on STN: 1996

L14 ANSWER 69 OF 85 MEDLINE on STN DUPLICATE 9
ACCESSION NUMBER: 95256642 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7537777
TITLE: Evidence that stratum corneum chymotryptic enzyme is
transported to the stratum corneum extracellular space via
lamellar bodies.
AUTHOR: Sondell B; Thornell L E; Egelrud T
CORPORATE SOURCE: Department of Dermatology, Umea University, Sweden.
SOURCE: The Journal of investigative dermatology, (1995 May) Vol.
104, No. 5, pp. 819-23.
Journal code: 0426720. ISSN: 0022-202X.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199506
ENTRY DATE: Entered STN: 15 Jun 1995
Last Updated on STN: 3 Mar 2000
Entered Medline: 2 Jun 1995

L14 ANSWER 70 OF 85 MEDLINE on STN DUPLICATE 10
ACCESSION NUMBER: 95314630 MEDLINE
DOCUMENT NUMBER: PubMed ID: 7794273
TITLE: Primary substrate specificity of recombinant human stratum corneum chymotryptic enzyme.
AUTHOR: Skytt A; Stromqvist M; Egelrud T
CORPORATE SOURCE: Astra-Hassle AB, Umea, Sweden.
SOURCE: Biochemical and biophysical research communications, (1995 Jun 15) Vol. 211, No. 2, pp. 586-9.
Journal code: 0372516. ISSN: 0006-291X.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199507
ENTRY DATE: Entered STN: 7 Aug 1995
Last Updated on STN: 3 Mar 2000
Entered Medline: 24 Jul 1995

L14 ANSWER 71 OF 85 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 1996:49666 BIOSIS
DOCUMENT NUMBER: PREV199698621801
TITLE: Molecular cloning of bomapin, a novel human serine proteinase inhibitor that is expressed specifically in the bone marrow.
AUTHOR(S): Riewald, M.; Schleef, R. R.
CORPORATE SOURCE: Dep. Vasc. Biol., Scripps Res. Inst., La Jolla, CA, USA
SOURCE: Blood, (1995) Vol. 86, No. 10 SUPPL. 1, pp. 496A.
Meeting Info.: 37th Annual Meeting of the American Society of Hematology. Seattle, Washington, USA. December 1-5, 1995.
CODEN: BLOOAW. ISSN: 0006-4971.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LANGUAGE: English
ENTRY DATE: Entered STN: 2 Feb 1996
Last Updated on STN: 13 Mar 1996

L14 ANSWER 72 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:790986 HCAPLUS
DOCUMENT NUMBER: 123:279485
TITLE: Production and characterization of recombinant human proteinase inhibitor 6 expressed in Pichia pastoris
AUTHOR(S): Sun, Jiuru; Coughlin, Paul; Salem, Hatem H.; Bird, Phillip
CORPORATE SOURCE: Department of Medicine, Monash Medical School, Box Hill Hospital, Box Hill, 3128, Australia
SOURCE: Biochimica et Biophysica Acta, Protein Structure and Molecular Enzymology (1995), 1252(1), 28-34
CODEN: BBAEDZ; ISSN: 0167-4838
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

L14 ANSWER 73 OF 85 MEDLINE on STN DUPLICATE 11

ACCESSION NUMBER: 94308225 MEDLINE

DOCUMENT NUMBER: PubMed ID: 8034709

TITLE: Cloning, expression, and
characterization of stratum corneum chymotryptic enzyme. A
skin-specific human serine
proteinase.

AUTHOR: Hansson L; Stromqvist M; Backman A; Wallbrandt P; Carlstein
A; Egelrud T

CORPORATE SOURCE: Symbicom AB, Umea, Sweden.

SOURCE: The Journal of biological chemistry, (1994 Jul 29) Vol.
269, No. 30, pp. 19420-6.
Journal code: 2985121R. ISSN: 0021-9258.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

OTHER SOURCE: GENBANK-L33404; GENBANK-M16117; GENBANK-M24400;
GENBANK-M25629; GENBANK-M64269; GENBANK-X05332;
GENBANK-X15505

ENTRY MONTH: 199408

ENTRY DATE: Entered STN: 25 Aug 1994
Last Updated on STN: 3 Mar 2000
Entered Medline: 18 Aug 1994

L14 ANSWER 74 OF 85 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on
STN

ACCESSION NUMBER: 1994:439498 SCISEARCH

THE GENUINE ARTICLE: NX327

TITLE: PROSTASIN IS A NOVEL HUMAN SERINE
PROTEINASE FROM SEMINAL FLUID - PURIFICATION,
TISSUE DISTRIBUTION, AND LOCALIZATION IN PROSTATE-GLAND

AUTHOR: YU J X (Reprint); CHAO L; CHAO J

CORPORATE SOURCE: MED UNIV S CAROLINA, DEPT BIOCHEM & MOLEC BIOL,
CHARLESTON, SC 29425

COUNTRY OF AUTHOR: USA

SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (22 JUL 1994) Vol. 269,
No. 29, pp. 18843-18848.
ISSN: 0021-9258.

PUBLISHER: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650
ROCKVILLE PIKE, BETHESDA, MD 20814.

DOCUMENT TYPE: Article; Journal

FILE SEGMENT: LIFE

LANGUAGE: English

REFERENCE COUNT: 40

ENTRY DATE: Entered STN: 1994
Last Updated on STN: 1994
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L14 ANSWER 75 OF 85 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on
STN

ACCESSION NUMBER: 1994:383895 SCISEARCH

THE GENUINE ARTICLE: NR314

TITLE: HOMOLOGY MODELING OF THE CATALYTIC DOMAIN OF HUMAN FURIN -
A MODEL FOR THE EUKARYOTIC SUBTILISIN-LIKE PROPROTEIN
CONVERTASES

AUTHOR: SIEZEN R J (Reprint); CREEMERS J W M; VANDEVEN W J M

CORPORATE SOURCE: NETHERLANDS INST DAIRY RES, DEPT BIOPHYS CHEM, POB 20,
6710 BA EDE, NETHERLANDS (Reprint); CATHOLIC UNIV LEUVEN,
CTR HUMAN GENET, MOLEC ONCOL LAB, B-3000 LOUVAIN, BELGIUM

COUNTRY OF AUTHOR: NETHERLANDS; BELGIUM

SOURCE: EUROPEAN JOURNAL OF BIOCHEMISTRY, (1 JUN 1994) Vol. 222,
No. 2, pp. 255-266.

ISSN: 0014-2956.
 PUBLISHER: BLACKWELL PUBLISHING LTD, 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND.
 DOCUMENT TYPE: Article; Journal
 LANGUAGE: English
 REFERENCE COUNT: 62
 ENTRY DATE: Entered STN: 1994
 Last Updated on STN: 1994
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L14 ANSWER 76 OF 85 MEDLINE on STN DUPLICATE 12
 ACCESSION NUMBER: 94043294 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 8227002
 TITLE: Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli.
 AUTHOR: Chai K X; Chen L M; Chao J; Chao L
 CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston 29425.
 CONTRACT NUMBER: HL44083 (NHLBI)
 SOURCE: The Journal of biological chemistry, (1993 Nov 15) Vol. 268, No. 32, pp. 24498-505.
 Journal code: 2985121R. ISSN: 0021-9258.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199312
 ENTRY DATE: Entered STN: 17 Jan 1994
 Last Updated on STN: 3 Feb 1997
 Entered Medline: 13 Dec 1993

L14 ANSWER 77 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1992:249902 HCAPLUS
 DOCUMENT NUMBER: 116:249902
 TITLE: Serine protease 3 from Wegener's granulomatosis patient and cDNA encoding it
 INVENTOR(S): Jenne, Dieter E.; Tschopp, Juerg; Luedemann, Jens; Utecht, Bert; Gross, Wolfgang L.
 PATENT ASSIGNEE(S): Gesellschaft fuer Biotechnologische Forschung m.b.H. (GBF), Germany
 SOURCE: PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9200378	A1	19920109	WO 1991-EP1142	19910620
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
EP 535059	A1	19930407	EP 1991-911228	19910620
EP 535059	B1	19951129		
R: AT, BE, CH, DE, DK, FR, GB, IT, LI, NL, SE				
JP 05507848	T2	19931111	JP 1991-510546	19910620
JP 3268777	B2	20020325		
AT 130871	E	19951215	AT 1991-911228	19910620
PRIORITY APPLN. INFO.:			DE 1990-4019984	A 19900622
			WO 1991-EP1142	W 19910620

L14 ANSWER 78 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1991:600349 HCAPLUS
 DOCUMENT NUMBER: 115:200349
 TITLE: Cytotoxic T cell protease cDNA and protease inhibitors
 INVENTOR(S): Bleackley, Robert C.; Lobe, Corrine G.; Paetkau, Verner H.; James, Michael N. G.; Murphy, Michael
 PATENT ASSIGNEE(S): Seragen, Inc., USA
 SOURCE: PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9110685	A1	19910725	WO 1991-US340	19910117
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2074081	AA	19910720	CA 1991-2074081	19910117
EP 511302	A1	19921104	EP 1991-903747	19910117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05506569	T2	19930930	JP 1991-503593	19910117
PRIORITY APPLN. INFO.:			US 1990-467880	A 19900119
			WO 1991-US340	W 19910117

L14 ANSWER 79 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1991:672672 HCAPLUS
 DOCUMENT NUMBER: 115:272672
 TITLE: Cloning and expression of human serine proteinase inhibitor cDNA
 INVENTOR(S): Kalsheker, Noor Ahmed
 PATENT ASSIGNEE(S): 3i Research Exploitation Ltd., UK
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9109947	A1	19910711	WO 1990-GB2003	19901221
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2070399	AA	19910623	CA 1990-2070399	19901221
EP 506755	A1	19921007	EP 1991-901314	19901221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05502376	T2	19930428	JP 1991-501703	19901221
US 5412073	A	19950502	US 1992-859480	19920616
PRIORITY APPLN. INFO.:			GB 1989-29110	A 19891222
			WO 1990-GB2003	W 19901221

L14 ANSWER 80 OF 85 MEDLINE on STN DUPLICATE 13

ACCESSION NUMBER: 91244893 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 2037625
 TITLE: Plasminogen activators and inhibitors in the neuromuscular system: III. The serpin protease nexin I is synthesized by muscle and localized at neuromuscular synapses.
 AUTHOR: Festoff B W; Rao J S; Hantai D
 CORPORATE SOURCE: Neurobiology Research Laboratory, Veterans Affairs Medical Center, Kansas City, Missouri 64128.
 SOURCE: Journal of cellular physiology, (1991 Apr) Vol. 147, No. 1, pp. 76-86.

PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199107
ENTRY DATE: Entered STN: 19 Jul 1991
Last Updated on STN: 19 Jul 1991
Entered Medline: 3 Jul 1991

L14 ANSWER 81 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1990:192953 HCAPLUS
DOCUMENT NUMBER: 112:192953
TITLE: Cloning of a gene that encodes a new member
of the human cytotoxic cell protease family
AUTHOR(S): Meier, M.; Kwong, P. C.; Fregeau, C. J.; Atkinson, E.
A.; Burrington, M.; Ehrman, N.; Sorensen, O.; Lin, C.
C.; Wilkins, J.; Bleackley, R. C.
CORPORATE SOURCE: Dep. Biochem., Univ. Alberta, Edmonton, AB, T6G 2H7,
Can.
SOURCE: Biochemistry (1990), 29(17), 4042-9
CODEN: BICHAW; ISSN: 0006-2960
DOCUMENT TYPE: Journal
LANGUAGE: English

L14 ANSWER 82 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1990:511415 HCAPLUS
DOCUMENT NUMBER: 113:111415
TITLE: Studies on the antiproteolytic activity of the two
domain structure proteinase inhibitor
"antileukoprotease"
AUTHOR(S): Meckelein, B.; Nikiforov, T.; Appelhans, H.
CORPORATE SOURCE: Inst. Biochem., Tech. Hochsch. Darmstadt, Darmstadt,
6100, Fed. Rep. Ger.
SOURCE: DECHEMA Biotechnology Conferences (1989), 3(Pt. A, Jt.
Meet. SIM DECHEMA, Presentation Biochem. Lab., Microb.
Princ. Bioprocesses, Appl. Genet.), 297-300
CODEN: DBCOEU; ISSN: 0934-3792
DOCUMENT TYPE: Journal
LANGUAGE: English

L14 ANSWER 83 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1989:511537 HCAPLUS
DOCUMENT NUMBER: 111:111537
TITLE: Comparative molecular model building of two serine
proteinases from cytotoxic T lymphocytes
AUTHOR(S): Murphy, Michael E. P.; Moulton, John; Bleackley, R.
Chris; Gershenfeld, Howard; Weissman, Irving L.;
James, Michael N. G.
CORPORATE SOURCE: Dep. Biochem., Univ. Alberta, Edmonton, AB, T6G2H7,
Can.
SOURCE: Proteins: Structure, Function, and Genetics (1988),
4(3), 190-204
CODEN: PSFGEY; ISSN: 0887-3585
DOCUMENT TYPE: Journal
LANGUAGE: English

L14 ANSWER 84 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:140893 HCAPLUS
DOCUMENT NUMBER: 114:140893
TITLE: Cantharide acantholysis: endogenous protease
activation leading to desmosomal plaque dissolution
AUTHOR(S): Bertaux, B.; Prost, C.; Heslan, M.; Dubertret, L.
CORPORATE SOURCE: Lab. Dermatol., Hop. Henri Mondor, Creteil, Fr.

SOURCE: British Journal of Dermatology (1988), 118(2), 157-65
 CODEN: BJDEAZ; ISSN: 0007-0963

DOCUMENT TYPE: Journal
 LANGUAGE: English

L14 ANSWER 85 OF 85 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1987:61853 HCAPLUS
 DOCUMENT NUMBER: 106:61853
 TITLE: Molecular analysis of the serine proteinase inhibitor
 gene family
 AUTHOR(S): Kidd, Vincent J.; Woo, Savio L. C.
 CORPORATE SOURCE: Howard Hughes Med. Inst., Baylor Coll. Med., Houston,
 TX, 77030, USA

SOURCE: Research Monographs in Cell and Tissue Physiology
 (1986), 12(Proteinase Inhib.), 421-40
 CODEN: RMTPD8; ISSN: 0378-6129

DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

=> d his

(FILE 'HOME' ENTERED AT 15:40:36 ON 14 NOV 2006)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS,
 LIFESCI' ENTERED AT 15:41:25 ON 14 NOV 2006

L1 38020 S SERINE (W) PROTEINASE?
 L2 8014433 S CLON? OR EXPRESS? OR RECOMBINANT
 L3 12818 S L1 AND L2
 L4 6935 S HUMAN AND L3
 L5 0 S E ANTALIS T M/AU
 E ANTALIS T M/AU
 L6 204 S E3
 E HOOPER J D/AU
 L7 89 S E3
 L8 268 S L6 OR L7
 L9 38 S L4 AND L8
 L10 26 DUP REM L9 (12 DUPLICATES REMOVED)
 L11 214 S HUMAN (W)L1
 L12 12818 S L2 AND L3
 L13 129 S L2 AND L11
 L14 85 DUP REM L13 (44 DUPLICATES REMOVED)